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ABSTRACT 
Crystallographic Studies for Structure-Based Drug Design1 
Natalie J. Tatum 
 
Structure-based drug design is an iterative design cycle reliant upon lead fragments 
and a known target. The result is two separate avenues of structure-based drug design, 
explored in this thesis: speculative, with no defined target (in the form of peptoid 
precursors) and rational, with a characterized target (in the form of EthR inhibitors).  
 Peptoids are N-substituted glycine molecules, able to mimic peptide structure 
and function with notable advantages for drug delivery and independent function. 
Here, the structures of two precursor molecules are presented as part of a wider aim to 
produce a tool-box of peptoid monomers for a fragment-based approach. The 
intramolecular interactions made by the two precursors can be extrapolated for the 
final peptoid. 
 EthR is a transcriptional repressor from Mycobacterium tuberculosis, a part of 
the activation pathway for the second-line drug ethionamide. It has been shown that 
inhibition of EthR results in a conformational change which renders the protein 
inactive, resulting in an increase in the bioactivation of ethionamide and so increased 
drug efficiency. Inhibitors for EthR have been designed, able to effect this response in 
vitro and in vivo.  
 This thesis details the crystallisation and structural study of peptoid precursors 
for use as lead fragments or monomers for peptoid click chemistry; and EthR inhibitors 
for improving the bioactivation and efficacy of ethionamide, with evaluation by 
molecular docking analysis in AutoDock Vina. The results show that shorter ligands, 
capable of engaging certain residues in the ligand-binding channel, are rated highest 
and so indicated to be the more effective inhibitors. 
 The two approaches highlight the diversity of tactics for new therapeutics and 
the powerful advantage of three-dimensional crystal structures, acquired through X-ray 
crystallography, to the drug design process. 
  
                                                                
The copyright of this thesis rests with the author. No quotation from it should be published 
without the prior written consent and information derived from it should be 
acknowledged.  
 
 
 
 
 
ACKNOWLEDGEMENTS 
 
 
Foremost, I would like to thank Dr. Ehmke Pohl for the invaluable, unwavering support 
and guidance he has given me throughout this year; it would be an understatement to 
say that this would not have been possible without him. 
 Secondly, to Dr. Martin Cann, Dr. Gary Sharples, Dr. Victoria Money and my 
friends and colleagues in CG231 for their advice and for enlightening tea-time 
conversations on the important questions of life, the universe and everything.  
 I’d like to thank Dr. Steven Cobb for allowing me to make a little slice of his 
work my own; and the same to Dr. Alain Baulard and Dr. Nicolas Willand at the Institut 
Pasteur de Lille and Université de Lille respectively, with added thanks for an 
interesting and informative trip to their labs in France. They have each been very 
generous with their time and work and I am exceptionally grateful. 
 Finally, I would like to take this opportunity to thank my parents for their 
endless encouragement, their unswerving support, and for never, ever letting me give 
up. In the end, none of this would have been imaginable, let alone possible, without my 
mum and dad; I cannot possibly thank them enough.  
 So this thesis is dedicated to my parents, for their dedication to me.  
 
 
 
 
i 
CONTENTS 
 page 
Chapter 1 Introduction 1 
Chapter 2 Background 3 
2.1 Peptoids 3 
2.1.1 Peptoids as transport signals 3 
2.1.2 Peptoids with intrinsic drug action 4 
2.1.3 Peptoid secondary structure 5 
2.2 Inhibitors of EthR, co-drug candidates for ethionamide in TB 
treatment 
6 
2.2.1 The life cycle of Mycobacterium tuberculosis 6 
2.2.2 Ethionamide is a second-line drug for TB treatment 7 
2.2.3 Bioactivation of ETH: The story so far and the possible targets for 
improvement 
9 
2.2.4 EthR is part of the TetR protein family 10 
2.2.5 Determining EthR function 12 
2.2.6 The crystal structure(s) of EthR 13 
2.2.7 Design and structure of EthR inhibitors 16 
2.2.8 Inhibitor binding to EthR 17 
2.2.9 Structural modifications to the inhibitors 19 
2.2.10 In vitro and in vivo testing of EthR inhibitors 20 
2.2.11 Project Aims 22 
2.3 An introduction to X-ray crystallography 23 
2.3.1 X-ray diffraction by crystals 23 
2.3.2 The crystal lattice 24 
2.3.3 Miller indices 25 
2.3.4 Combining waves to give an image of electron density: the phase 
problem 
26 
2.3.5 Solving structures in chemical crystallography 27 
2.3.6 Refining structures in chemical crystallography 29 
Chapter 3 Methods 32 
3.1 Introduction to the crystallisation of small organic compounds 32 
3.1.1 Method: Initial solubility screens 34 
3.1.2 Theory: Crystallisation by Evaporation 35 
3.1.3 Theory & Method: Crystallisation by Liquid Diffusion 36 
3.1.4 Theory & Method: Crystallisation by Vapour Diffusion 38 
3.1.5 Method: Crystallisation of an anionic peptoid precursor 39 
3.1.6 Method: Crystallisation of a protonated peptoid precursor 39 
3.1.7 Ongoing crystallisation attempts of peptoid precursor molecules 40 
3.1.8 Method: Crystallisation of BDM31343 40 
3.1.9 Method: Crystallisation of BDM41420 41 
3.1.10 Method: Crystallisation of BDM41907 41 
3.1.11 Method: Crystallisation of BDM41325 41 
3.1.12 Ongoing crystallisation attempts of EthR inhibitors 42 
3.2 X-ray diffraction experiments 44 
3.2.1 Choosing a crystal 44 
3.2.2 Harvesting a crystal 44 
3.2.3 Screening crystals 45 
3.2.4 Data collection 46 
3.2.5 Data processing 48 
3.3 Autodock Vina 49 
 
 
 
 
ii 
3.3.1 Theory: Molecular docking 49 
3.3.2 Using Vina 49 
3.3.3 Testing Vina 51 
3.3.4 Method: Vina applied to EthR inhibitors 51 
Chapter 4 Results and Discussion: Peptoids 53 
4.1 Anionic Peptoid Precursor 53 
4.1.1 Structural analysis 54 
4.1.2 Crystal packing interactions 55 
4.2 Protonated peptoid precursor 57 
4.2.1 Structural analysis 57 
4.2.2 Crystal packing interactions 58 
4.3 Implications for use as peptoids 60 
Chapter 5 Results and Discussion: EthR Inhibitors 61 
5.1 BDM31343 61 
5.2 BDM41420 63 
5.3 BDM41907 65 
5.4 BDM41325 67 
5.5 Molecular docking of EthR inhibitors 69 
5.5.1 Molecular docking of BDM31343 69 
5.5.2 Molecular docking of BDM41420 71 
5.5.3 Molecular docking of BDM41907 73 
5.5.4 Molecular docking of BDM41325 75 
Chapter 6 Conclusions & Moving Forward 77 
6.1 Peptoid Precursors 77 
6.2 EthR inhibitors 77 
6.2.1 Docking results 77 
6.2.2 Evaluation of Autodock Vina 78 
6.2.3 Moving forward 80 
References  81 
Appendix  87 
A-I Anionic peptoid precursor 87 
A-II Peptoid peptoid precursor 90 
A-III BDM31343 93 
A-IV BDM41420 95 
A-V BDM41907 98 
A-VI BDM41325 102 
 
  
 
 
 
 
iii 
LIST OF FIGURES 
Figure  page 
2.1 Schematic of a peptide and a N-substituted glycine peptoid 3 
2.2 Chemical structures of ethionamide and isoniazid 8 
2.3a ETH-NAD adduct from InhA co-crystal structure 9 
2.3b Chemical structures of potential ETH bioactivation intermediates 10 
2.4 Schematic of the ethA-R intergenic region 11 
2.5 Crystal structure of EthR in a ligand-bound conformation 14 
2.6 Pathway of the consequences of EthR inactivation 15 
2.7 Chemical structure of BDM14500 17 
2.8 BDM14500 bound to EthR 17 
2.9 Chemical structures of BDM31381 and two analogues 18 
2.10 Comparison of ligands in the EthR ligand binding channel 19 
2.11 Radial diffusion experiments with BDM14500 20 
2.12 Chemical structures of BDM31381 and BDM31343 21 
2.13 Schematic of a unit cell 23 
2.14 Lattice points and lattice planes 24 
2.15 Bragg’s law – constructive and destructive interference of waves 25 
2.16 Assigning Miller indices 25 
2.17 Geometry of a periodic wave 26 
3.1 Phase diagram of crystallisation 33 
3.2 Solubility screens 34 
3.3 Schematic of a liquid diffusion experiment 36 
3.4 Schematic of a vapour diffusion experiment 38 
3.5 Examples of crystals of BDM31343 grown by evaporation of NMP 40 
3.6 A crystal of BDM41325 mounted on a glass fibre 45 
3.7 Schematic of a three-ring diffractometer 47 
3.8 Log file of a Vina run 50 
3.9 Basic configuration file used for Vina runs on inhibitor structures 52 
4.1 Asymmetric unit of the anionic peptoid precursor 53 
4.2 Cell-centred image of the anionic peptoid precursor structure 54 
4.3 Geometry of the sodium ion co-ordination 54 
4.4 Crystal structure of the anionic peptoid precursor 56 
4.5 Asymmetric unit of the protonated peptoid precursor 57 
4.6 Cell-centred image of the protonated peptoid precursor 57 
4.7 Crystal packing in the protonated peptoid precursor 58 
4.8 Schematic for peptoid preparation from these precursors 60 
4.9 Chemical structure of a potential peptoid 60 
5.1 Asymmetric unit of BDM31343 61 
5.2 Chemical structure of BDM31343 61 
5.3 Crystal packing structure of BDM31343 62 
5.4 Asymmetric unit and overlay of BDM41420 63 
5.5 Crystal packing of BDM41420 64 
5.6 Asymmetric unit of BDM41907 65 
5.7 Crystal packing structure of BDM41907 66 
5.8 Asymmetric unit of BDM41325 67 
5.9 Crystal packing structure of BDM41325 68 
5.10 Comparison of four highest ranked BDM31343 binding modes 69 
5.11 Overlay of BDM31343 binding mode 1 with the original ligand 70 
5.12 Key residue interactions of docked BDM31343 70 
5.13 Overlay of BDM41420 binding mode 1 with the original ligand 71 
 
 
 
 
iv 
5.14 Comparison of four highest ranked BDM41420 binding modes 71 
5.15 Key residue interactions of docked BDM41420 72 
5.16 Overlay of BDM41907 binding mode 1 with the original ligand 73 
5.17 Comparison of four highest ranked BDM41907 binding modes 73 
5.18 Key residue interactions of docked BDM41907 74 
5.19 Overlay of BDM41325 binding mode 1 with the original ligand 75 
5.20 Comparison of four highest ranked BDM41325 binding modes 75 
5.21 Key residue interactions of docked BDM41325 (mode  1) 76 
5.22 Key residue interactions of docked BDM41325 (mode 3) 76 
A1 Labelled 50% probability ellipsoid structure of the anionic 
peptoid precursor 
88 
A2 Labelled 50% probability ellipsoid structure of the protonated 
peptoid precursor 
90 
A3 Labelled 50% probability ellipsoid structure of BDM31343 94 
A4 Labelled 50% probability ellipsoid structure of BDM41420(1) 96 
A5 Labelled 50% probability ellipsoid structure of BDM41420(2) 97 
A6 Labelled 50% probability ellipsoid structure of BDM41907 99 
A7 Labelled 50% probability ellipsoid structure of BDM41325 102 
 
 
 
 
 
 
1 
CHAPTER 1 
INTRODUCTION 
 
Structural characterisation of chemical compounds has a variety of benefits. Foremost, 
a crystal form can be used to assess the physical attributes of the compound - from 
bond lengths and angles, to the torsions of individual groups – in the absence of other, 
potentially structure-altering molecules. Therefore, all intermolecular interactions 
made are unique to the compound, and can be used in the drug design process to 
optimise the design for a target or particular purpose.  
 X-ray crystallography is the most important method available to accurately 
determine the structure of a compound in three dimensions, and so is a powerful tool 
in chemical studies and the drug design process. Crystallisation of an active 
pharmaceutical ingredient is especially important for patenting, particularly for the 
pharmaceutical companies which commit large sums of money towards research into 
novel drug compounds. Patents are granted for single crystalline forms – typically the 
dosage form – and polymorphs, hydrates and salts etc. constitute separate patents (or 
aspects of a portfolio) which can prove lucrative while also protecting a new 
development.  
 In addition, through crystallisation, diffractometry and structure solution, 
molecular modelling can be used to inform the compound design and make predictions 
for protein-ligand binding without the need for expending resources on biological assay 
and co-crystallisation. 
 This thesis details two aspects of the rational drug design process. Firstly, the 
creation of lead fragments and sub-units which can be used as a base to develop active 
drugs: in this case, peptoid monomers. Peptoids, small amino-acid chain mimics, are 
proven drug alternatives for peptide therapies.1 The well-defined secondary structures 
that peptoid oligomers create when linked make for a reliable drug which can have 
action in its own right, or act as a cellular target or transporter signal.2,3 Characterising 
the structure of peptoid monomers in isolation and combination could lead to a 
database of three-dimensional co-ordinates, which can be used to create lead fragments 
or signal molecules with known and defined conformations. 4 
  The second focus of this research project is a structure-based drug design 
process: a known target, for which the structure has been determined, is used as a 
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template to design molecules to affect a particular, desired response. Tuberculosis 
poses a global world health crisis, and drug resistance is on the rise; new targets for 
treatment are needed in order to make headway in reducing the rising incidence rate.5,6 
 EthR, a transcriptional regulator in Mycobacterium tuberculosis, has been 
proven to be a viable drug target in treatment of tuberculosis;7,8 inhibitors of this 
protein delivered in conjunction with the anti-TB drug ethionamide (ETH) have been 
shown to reduce the bacterial load as effectively as a three times higher dose of ETH 
alone.9 Acquiring the crystal structures of these inhibitors in isolation will not only give 
insight into the conformation the molecule takes in the absence of the target protein, 
but also inform the further design process. Optimisation of the inhibitor design 
requires extensive biophysical assessment if conducted in vivo and in vitro; molecular 
docking with software AutoDock Vina can use the crystal structure of the inhibitor to 
predict binding conformations in the protein crystal structure.10 Docking studies will 
allow in silico examination of the putative protein-ligand complex. 
 The project itself relies upon the ability to successfully crystallise the 
compounds for X-ray diffraction analysis; this is not always guaranteed, not least due to 
the small amounts of each compound provided. This thesis will detail the background 
of the two avenues of my research project on the structural features of drug and 
intermediate molecules. The methods used in the endeavour to grow crystals for 
analysis will be explained, as well as the implications from the data acquired by X-ray 
diffraction and molecular docking analyses. Finally, conclusions will be drawn from the 
data which will be used to further the research being conducted in these areas. 
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CHAPTER 2 
BACKGROUND 
2.1 | Peptoids 
Peptoids are defined as N-substituted glycine molecules which mimic α-amino acid 
peptides when oligomerised (figure 2.1). The term derives from ‘peptidomimetic’, 
which was introduced to indicate that although peptoids are structurally distinct from 
peptides, they have been shown to mimic peptide biological function. When first 
developed, they were envisioned as a customisable library of lead compounds for drug 
discovery.1 However, they have since been revealed to be useful molecules in their own 
right.11 
 In practical terms, peptoids can be both drugs and drug delivery agents, vastly 
outclassing peptide therapies. As drugs, peptides are particularly desirable due to their 
ability to bind both proteins and DNA effectively. However, their sensitivity to 
proteases and the limited ability to cross the cell wall of a target are clear stumbling 
blocks when it comes to using peptides as antimicrobial agents. Peptoids, with their 
intrinsic resistance to proteolysis and the potential to be designed with greater cell 
permeability, are a proven alternative.4 
 
                 
Figure 2.1 | An N-substituted glycine template for peptoids and a classic α peptide.1 
 
2.1.1 | Peptoids as transport signals 
The ability to cross the cell membrane is of particular importance to using peptides or 
peptoids as drug molecules. Peptides are largely polar, hydrophilic molecules which are 
difficult to transport across the hydrophobic, lipophilic cell membrane. However,  
peptoids analogous to peptide sequences have been shown to be more cell-permeable 
by a factor of up to 20-fold.12 This gives peptoids great potential in drug delivery or 
targeting.  
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 Peptoid sequences have been successfully used as transporter sequences to 
target drug molecules across cell membranes. For example, the HIV type I Tat protein is 
an extracellular protein which enters target cells to facilitate viral replication. It is able 
to do this by an arginine-rich sequence which allows active cellular uptake.13  The 
truncated sequence from HIV Tat-1 has been capably used as a drug transporter, as 
have similar poly-lysine and poly-arginine peptides; it has been put to use recently to 
deliver a putative tumor repressor protein to hepatoma cells (Chen et al. 2011). 
Therefore, an analogous peptoid was designed and shown to be resistant to proteases, 
cheaper and more efficiently produced, and crucially was a better transporter than the 
original Tat sequence.3 
 Substitution of arginine and lysine residues in an insect antimicrobial peptide 
with NArginine peptoid monomers (ie. the arginine side chain is attached to the 
nitrogen rather than the Cα) had a reduced effect compared to pure peptoid transport 
sequences. The peptoid-peptide hybrid was able to cross the plasma membrane and did 
not show cytotoxic activity; as the substitutions were placed closer to the C-terminal, 
the hybrid displayed reduced antimicrobial activity.15  
 Furthermore, a library of around 50,000 synthetic peptoids was screened for 
the ability to bind a specific activation domain of the CREB-binding protein. The hits 
resulted in synthetic transcription factor mimics which were found to show a 5-fold 
increase in the reporter gene expression (luciferase in cultured mammalian cells) 
compared to native transcription factors. The response was also highly selective within 
the cell, meaning the peptide-peptoid hybrid is specific to the target gene. This is a 
promising result for peptoid hybrid therapeutics.16 
 
2.1.2 | Peptoids with intrinsic drug action 
Peptoids can also have drug action in their own right, proving successful in binding 
crucial, shallow regions on the surfaces of important targets – for example, the vascular 
endothelial growth factor receptor 2, VEGFR2.17 Though some clinical successes have 
been found among peptides, their development is hindered by the various drawbacks 
to peptides as drugs. Peptoid ligands were found for VEGFR2 through a screening of a 
peptoid library, and a dimeric peptoid was found to not only interact solely with the 
receptor, but was an agonist of its function in vitro.2  
 In a pre-clinical mouse model, this dimeric peptoid was also seen to have an in 
vivo agonising effect on tumour growth – smaller tumours and a reduced tumour 
growth rate were observed in comparison to the control animals. Peptoids have also 
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been seen to inhibit the interaction between HDM2 and p53; over-expression of the 
former has been linked to aggressive tumours and drug resistance.18 
 Peptoid ligands have also been designed with both agonist and antagonist 
function against neuropeptide receptors; this has potential applications in hormonal 
and physiological conditions.19 
 In early 2011, a paper was published showing peptoids as potential ‘capture 
agents’ for antibody biomarkers in diseases such as Alzheimer’s Disease and multiple 
sclerosis; the initial studies on mouse models and AD patients (with healthy control 
patients) have since expanded.20 Direct peptoid-based therapies are therefore a 
clinically viable option to current medical conundrums. 
 
2.1.3 | Peptoid secondary structure 
The key to all of the aforementioned peptoid uses is the ability to fine-tune the peptoid 
spatial structure through different N-substituted glycine monomers. Peptoid side 
chains, placed on the amide nitrogen, are crucial to peptoid function.  The folding of the 
oligomeric peptoid is dictated by these side chains and their effect on the achiral 
backbone. Without any amide hydrogens in this backbone, there can be no intra-chain 
hydrogen bond formation. This makes the peptoid chain very flexible, but including 
monomers with large side chains will restrict the conformations the oligomer is able to 
adopt; aromatic side chains form intramolecular stacking interactions and electron 
deficient groups have been observed to stabilise the secondary structure through 
interactions with the backbone. It follows that, just as in peptides, the primary 
structure determines the secondary structure adopted, and peptoids have well-defined 
secondary structures.21 Folded peptoid conformations can be analogous to α-peptides, 
even when amino acids are replaced like-for-like with their N-substituted 
counterparts.22 
 With such well-defined secondary structures derived from the primary 
sequence, and a history of using peptoid libraries as a starting point in determining 
drug candidates, well-characterised monomers can be of great use with an eventual 
‘toolbox’ of peptoid monomers with known conformations to be screened for use on a 
wide range of targets. 
 
  
 
 
 
 
6 
2.2 | Inhibitors of EthR, co-drug candidates for ethionamide in TB treatment 
Tuberculosis remains a global health crisis. It is anticipated that 2011 will see close to 
10 million cases of tuberculosis (TB) worldwide.23 While global incidence rates per 
capita are falling year on year by an average of 1%, the global population is increasing 
by 2% at the same rate; the absolute number of new cases of tuberculosis is in fact 
rising. This epidemic, which is controlled in Western Europe and the United States, is 
uncontrollable in sub-Saharan Africa, Eastern Europe and Asia due to high HIV co-
infection rates and poor access to effective healthcare. One issue which is common to 
poor TB control worldwide is the poor efficiency and observance of the Directly 
Observed and Short-Course therapy (DOTS), with a consequent rise in MDR-TB: multi-
drug resistant tuberculosis.5 
 
2.2.1 | The life cycle of Mycobacterium tuberculosis 
TB is caused by M. tuberculosis (Mtb), a Gram-positive mycobacterium which has an 
unusual, lipid-rich cell envelope. Mycolic acids are a vital component of the cell well, 
consisting of a β-hydroxy fatty acid, typically C54-C64 atoms long, and an α-branched C22-
C24 alkyl side chain.24 Characteristic cyclopropane rings in the chains of the mycolic acid 
have a structural and functional role, maintaining the integrity of this unique cell wall 
and protecting the wall and so the mycobacterium from oxidative stress – the primary 
defence of the mammalian immune system. This gives the bacilli a measure of 
resistance to the action of the host’s innate immune system, essential as the Mtb life 
cycle requires phagocytosis into alveolar macrophages in the host lungs.25 
 Transmission occurs by inhalation of bacilli (or even as few as a single bacillus) 
in liquid droplets, exhaled by a person with an active TB infection. The droplets are 
robust enough to remain airborne and transmissible for several hours. It is understood 
through animal models and studies of human TB progression that the inhaled bacteria 
are phagocytosed into macrophages on the alveolar epithelial surface; the 
mycobacterial cell wall fuses with the phagosome membrane, preventing lysosome 
fusion and attack upon the subsumed pathogen.26 Therefore, the bacteria are able to 
replicate in the host cell; the Mtb replication cycle takes 15-20 hours, a comparatively 
slow process when it is considered that the E. coli cycle is only 20 minutes; Mtb is 
protected within the macrophages of the mammalian immune system, and so speedy 
replication is not a priority. The infected macrophages migrate into the alveolar 
epithelial layer; this induces a localized inflammatory response, recruiting 
mononuclear cells from neighbouring blood vessels and providing the dividing bacteria 
with fresh host cells. 
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 A granuloma forms from the macrophages and recruited monocytes and 
neutrophils. The macrophages begin to differentiate; some fuse into giant 
multinucleated cells, some into cells filled with liquid droplets (‘foamy macrophages’). 
At 2-3 weeks after initial infection, Mtb-specific lymphocytes (of the acquired immune 
response) arrive at the site of infection and form a mantle around the centre of the 
granuloma. The rate of bacterial replication has slowed even further by this point, and 
cells are actively recruited to the vascularised granuloma to allow the infection to 
persist.27 
 A critical stage is reached when the population of foamy macrophages increases 
and the vascular structure undergoes necrosis. The granuloma eventually ruptures and 
collapses, releasing liquid droplets to the bacilli into the patient’s lungs; these droplets 
can then be dispersed in a cough and exhaled into the air. At any given time in an active 
infection, multiple granulomas may be present in the airways at differential stages of 
development, with bacteria utilising different metabolic pathways and regulatory 
systems over the course of the life cycle.  Drugs for the treatment of Mtb infection 
preferentially target replicating bacteria, when the bacilli are most vulnerable. 
However, this means that non-replicative bacilli, either dormant or established prior to 
drug delivery, will show an innate resistance to the chemotherapy.28,29 This leads to a 
treatment of up to two years with the Directly Observed Treatment Short-Course 
(DOTS) therapy.30 
 
2.2.2 | Ethionamide is a second-line drug for TB treatment 
The DOTS for TB consists of 8-10 drugs, including the front line antibiotics isoniazid 
and rifampicin, as well as second-line drugs such as pyrazinamide and ethionamide. The 
second-line drugs are not as efficient, with dose-related side-effects ranging from 
nausea and abdominal cramps to hepatotoxicity and neuropathies. With patients facing 
up to two years of such side-effects, it is no surprise that the treatment is often not fully 
observed and as a result, 30% of patients experience treatment failure.31 
Although isoniazid (INH) was identified as an anti-TB agent in the early 1950s, 
the mode of action was not identified until much later. Initial observations of the 
interference of INH with the formation of the cell envelope and mycolic acid synthesis 
were made by in 1970;32 two years later, it was shown that INH treatment leads to an 
immediate inhibition of mycolic acid synthesis.33 After 24 hours, growth of these drug-
treated bacilli had slowed to a complete halt. Viability was completely destroyed within 
a day, and provided INH treatment continued until this point, inhibition would be 
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permanent; if INH treatment stopped before cell viability was abolished, mycolic acid 
production would recover. 
 
Figure 2.2 | Chemical structures of ETH and INH 
The second-line drug ethionamide (ETH) is analogous to INH; the chemical structures of 
both can be seen in figure 2.2. While they have different bioactivation enzymes, 
controlled by distinct pathways, they share a common mode of action: inhibiting the 
enoyl-acyl reductase, InhA, of the fatty acid synthase II (FASII) system in Mtb.34 InhA 
preferentially reduces long-chain 2-trans-enoyl-ACP substrates of 12-14 carbons in 
length in an NADH-dependent manner. This is essential for fatty acid elongation, and so 
inhibition prevents the production of mycolic acids for the formation of the 
mycobacterial outer surface, derailing bacterial replication and causing the cells to 
lyse.35  
 Though INH and ETH have been in use since 1952 and 1957 respectively as 
anti- tubercular drugs, their target was not conclusively identified until 1994.36 The 
inhA gene was identified through INH-resistant clinical isolates of Mtb and a year later 
the protein product InhA was characterised – enzymatically37 and structurally.38 It was 
observed that the two substrates of InhA bound sequentially to the protein, with the 
NADH taking priority over the enoyl substrate. It was even later still that definitive 
evidence for the mode of action of INH and ETH was established, as described below.  
 
2.2.3 | Bioactivation of ETH: The story so far, and the possible targets for improvement 
The lack of cross-resistance seen between INH and ETH suggested a distinct activation 
process for ETH, independent of the catalase peroxidise enzyme KatG (responsible for 
INH-activation). ETH-resistant M. smegmatis isolates were used to identify an open 
reading frame (ORF) which, when disrupted, reversed this resistance. This ORF was 
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found to code a regulatory protein, termed EthR for its apparent role in ETH resistance 
and susceptibility. A neighbouring ORF was found to have homology to known mono-
oxygenases. When this putative mono-oxygenase was over-expressed in M. smegmatis, 
the mycobacteria became hypersensitive to ETH with a significant inhibition of mycolic 
acid synthesis with low ETH concentrations in comparison to the wild type. From this it 
was postulated that the supposed mono-oxygenase was the ETH activator, termed 
EthA. It was finally identified in 2000 as the protein product of the Mtb H37Rv gene 
Rv3854c. 39 
 EthA was confirmed to be a mono-oxygenase, metabolising ETH in a two-step 
process which is both NADPH and O2-dependent.40 The product of the first step is a 
sulphoxide derivative, ETH-SO; as for the second step, though various metabolites of 
ETH have been identified41 and characterised by NMR-based methods,42 and HPLC,43 
the ‘active’ and bacteriotoxic form of ETH has never been isolated. Instead, Wang et al. 
in 2007 published their crystal structures and showed the isolation of an ETH-NAD 
adduct tightly bound to InhA in the normal binding pocket for NADH (figure 2.3a). A 
pure fraction of this adduct was shown to strongly inhibit native InhA in vitro.44 
 
Figure 2.3a | The ETH-NAD adduct, derived from the co-crystal structure of the adduct with InhA (PDB: 
2H9I). Image created using PyMol.44 
 
What remains to be seen is the structure of the ETH metabolite which forms the 
covalent bond with NAD+. Vanelli et al. suggested the cytotoxic species as a sulphonic 
acid derivative of ETH-SO,40 however the later discovery of the inhibiting ETH-NAD 
adduct led Wang et al. to suggest a mechanism by which ETH- or ETH˙ is produced to 
react with NAD+; H2O then attacks the NH group to create the carboxyl group, as seen in 
figure 2.3b. 
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Figure 2.3b | The chemical structures of the potential intermediates of ETH bioactivation. 
 
How this putative anion or radical is formed is unclear: is an intermediate (and as yet 
unidentified) enzyme required to mediate the covalent bond formation, or does EthA 
produce this radical as well as facilitate binding to NADH? The presence of quenched 
metabolites would support the latter supposition, as it would not be possible for 100% 
of the radical produced at the membrane-bound EthA to react with cytosolic NADH and 
inhibit InhA. Radical species are exceptionally reactive and would be quenched as 
quickly as possible to prevent intracellular damage.  Added to this is the fact that EthA 
interacts with NADPH, not NADH, and while EthA certainly catalyses a second step, it 
remains unclear what this second step is. 
 
2.2.4 | EthR is part of the TetR protein family 
As previously stated, EthA expression is regulated by EthR, a protein encoded in a 
neighbouring open reading frame (figure 2.4) by the gene ethR. Under ethR over-
expression, ethA was seen to be repressed (independent of ETH treatment). In those 
samples treated with ETH, it was observed that the mycobacteria were less sensitive to 
the treatment. This suggests ethR over-expression represses ethA, which in turn leads 
to reduced bioactivation of ETH.45 
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Mycobacterium tuberculosis H37Rv gene assignments identified EthR (‘Rv3855’) as a 
probable member of the TetR family of transcriptional repressors based on the 
sequence identity within the family (25%) and the presence of a putative helix-turn-
helix motif, a well-known DNA-binding element.46,47 TetR, the tetracycline expression 
repressor, recognises and binds a 15bp stretch of the target Tn10 promoter.48 It was 
expected that EthR would bind DNA in a similar fashion, and experiments were 
undertaken to establish how EthR interacts with the ethA-R region. 
 
2.2.5 | Determining EthR function 
To determine the role of EthR in Mtb, the gene was cloned from M. tuberculosis H37Rv 
and expressed in E. coli. DNase I protection assays (by which a 323bp fragment 
containing the ethA-R intergenic region are subjected to DNase I digestion in the 
presence of purified His6-tagged EthR) revealed that EthR protects 55bp in the 75bp 
intergenic region. This is almost four times as long as that bound by TetR, indicating 
EthR binds as a multimer, potentially at separate binding sites.7 
 Surface plasmon resonance was used to determine the stoichiometry of the 
EthR-DNA interaction.  Initially, a 106bp biotinylated double-stranded DNA fragment 
covering the intergenic region was used as a ligand on the sensor chip. His6-EthR was 
then washed onto the surface of the chip at increasing concentrations until the protein 
was saturated with the available ligand. Using the known masses of the DNA fragment 
and protein (DNA fragment of 69kDa, and the Mr of His6-EthR being approximately 
25920) the ratio of DNA to protein remaining bound to the chip could be calculated. 
This revealed eight molecules of His6-EthR per 106bp DNA molecule. The SPR assay 
was repeated with a shorter 62bp fragment (which covered the 55bp region identified 
by DNase I foot-printing) and the same 8:1 stoichiometry was found. In the absence of 
the operator, EthR was seen to dimerise. All results taken together suggested EthR 
binds ethA-R as four homo-dimers.7   
 This extensive coverage of EthR on ethA-R suggests that the protein simply 
prevents RNA polymerase from binding the operator, repressing the expression of both 
genes. It follows that EthR auto-regulates its expression, a feature seen in other TetR-
family repressors,49 though no conclusive evidence has been presented to date to 
confirm this supposition. 
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2.2.6 | The crystal structure(s) of EthR 
The first crystal structures of EthR were solved in 2004.7,50 The two structures are 
identical, with an RMSD of 0.634 Å over 179 Cα atoms of the protein between residues 2 
and 200.51 These two separate groups working on EthR crystallised the protein in the 
same crystal form under different crystallisation conditions, indicating that the 
inhibited conformation is thermodynamically stable and packs very specifically, despite 
the two structures binding different ligands. 
 The structures confirmed the suspected similarity to TetR family repressors, 
including the N-terminal helix-turn-helix DNA-binding domain and the C-terminal 
ligand-binding domain (figure 2.5).  EthR is a functional homodimer with a structure 
composed of nine α-helices. The dimer associates through the formation of a four helix 
bundle, which is the association of two helices from each monomer (inset figure 2.5). 
 Ligand-binding in DNA-binding proteins such as the TetR family of repressors 
has a profound effect on the conformation of the homodimer. Active homodimeric DNA-
binding regulators must contact the major grooves of B-DNA, at a distance of 
approximately 34-Å.52 EthR in its ligand-bound conformation was found to have a 
distance between the DNA-binding domains of 52.49 Å; with a ligand such as HexOc 
bound, the DNA-binding domains are too far apart to functionally bind DNA.9 This 
essentially inactivates EthR. 
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Figure 2.5 | The crystal structure of EthR in a ligand-bound conformation (monomer a PDB: 1U9N; dimer c 
PDB: 1U9O). Image a shows the DNA-binding domain formed by the helix-turn-helix motif with a third, 
stabilising helix. Hexadecyl octanoate (b) was found within the six-helix ligand-binding domain. 7. 
 
EthR co-purified and co-crystallised with a ligand, hexadecyl octanoate (HexOc) in the 
ligand-binding domain.7 It has been postulated that this fortuitous ligand has a role in 
the in vivo regulation of EthR; as a potential by-product in mycolic acid synthesis, long 
esters binding EthR would provide a feedback system with which to regulate ethA 
expression.  
 The ligand binding site of EthR is rich in hydrophobic and aromatic residues, 
and an uncharged polar region is formed by Asn176, Asn179 and Thr149. It was 
expected that if a moderately lipophilic compound with the ability to hydrogen bond 
with these residues could bind with EthR, the inactive conformation could be induced.9 
 Figure 2.6 shows how this binding will affect ETH activity. In the presence of 
inhibited EthR, ethA expression increases, causing an increase in EthA protein and ETH 
bioactivation. The activated ETH binds to NAD+ to form the inhibitory adduct which 
prevents InhA from performing its role in mycolic acid synthesis. 
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2.2.7 | Design and Structure of EthR inhibitors 
In order to find suitable ligands for initial trials on EthR inhibition, a pharmacophore 
was designed to interrogate a virtual library of drug-like compounds.  Lipinski et al. 
describe four features which primarily determine the success of a molecule as an 
effective drug, with a computational method for quantification.53 These features, which 
determine good permeation and absorption, are: 
 a molecular weight lower than 500 
 fewer than 5 hydrogen bond donors 
 fewer than 5 hydrogen bond acceptors 
 a CLogP < 5 – calculated partition co-efficient, measuring miscibility in water 
Lipinski’s rules are typically referred to as the ‘rule of five’, not because there are five 
rules, but because the relative co-efficients of each feature are multiples of 5. To reflect 
the desired features, the pharmacophore had a low molecular weight, with two 
hydrophobic ends separated by a 4-6-Å linker. The linker included groups with the 
ability to hydrogen bond, designed to interact with the asparagine residues in the 
channel’s polar region.  
 The library contained 131 compounds which fit this basic pharmacophore. 
They varied in the nature of the hydrophobic ends (aromatic groups, aliphatic groups, 
cyclic and heterocyclic); the length and nature of the spacer varied, including triazole 
and oxadiazole groups; and some ends were substituted with alkyl chains, halogens and 
electron donating or withdrawing groups. The properties of each of these 131 highly-
varied compounds were computed and those with the “best compromise” of features 
according to Lipinski’s rules were taken forward into a functional screen. 
 The surface plasmon resonance (SPR) assay designed to determine the nature 
of the EthR-DNA interaction (described in section 2.2.5) was used to determine 
whether the compounds were capable of preventing EthR-DNA binding. Those that 
were able to inhibit EthR binding fell into two distinct structural categories. Those 
compounds possessing a 1,2,4-triazole linker were able to inhibit binding with an 
average of only 17%; compounds possessing a 1,2,4-oxadiazole linker were able to 
inhibit binding by over 50%. One of these oxadiazole-containing compounds was 
BDM14500.9 
 BDM14500, shown below in figure 2.7, was co-crystallised with EthR to 
determine the position it takes within the ligand-binding channel and if the compound 
was having the same conformation-induced inhibitory effect on EthR as was shown 
with HexOc. The crystal structure showed BDM14500 in the ligand-binding channel, as 
anticipated, with the oxadiazole linker within hydrogen bonding distance of Asn179. 
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BDM14500 bound to EthR can be seen in figure 2.8, below. Crucially, BDM14500 was 
able to effect a distance between the DNA-binding domains of the EthR dimer of 50.3-Å, 
the inhibited form of the repressor.9  
 
Figure 2.7 | The chemical structure of inhibitor BDM14500 
 
2.2.8 | Inhibitor binding to EthR 
With the ability of these drug-like molecules to inhibit EthR proven, analogues of 
BDM14500 were synthesised and evaluated by the same SPR assay. Of the resulting 
molecules, only those possessing the piperidyl ring were able to prevent EthR binding 
DNA. Two of these compounds were particularly effective: BDM31381 and BDM31343. 
These compounds were taken forward for biological assay, described in section 2.2.10. 
 
Figure 2.8 BDM14500 co-crystallised with EthR (PDB: 3G1O). The inset shows the molecule (in blue) 
bound in the ligand-binding channel where HexOc was bound. The orientation of the image has been 
changed for clarity. The labelled residues represent some of the side groups lining the channel, including 
the Asn176, Asn179 and Phe110 which surround the oxadiazole linker. The piperidinyl ring is in a pocket 
formed by Trp207, Trp103, and Ile107. Leu183 is part of the pocket in which the thienyl ring is contained. 
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The range of flexibility in the ligand-binding site was further tested by developing 
analogues of BDM31381 (figure 2.9). These analogues were created through in situ 
click chemistry, a method for the quick and reliable generation of new molecules by the 
assembly of small units.54 The compound BDM14801, synthesised through the 
replacement of the thienyl-acetyl group of BDM31381, was found to place itself in the 
same position in EthR and in a similar orientation to BDM31381, distinct from 
BDM14500 in that the thienyl-oxadiazole points to the aperture of the channel, rather 
than to the hydrophobic top, where the acetylazido group of BDM14801 was oriented 
(PDB: 3O8G). This made BDM14801 an ideal starting point from which to determine 
the range of flexibility allowed in this hydrophobic pocket.55 The main product of the 
tested click chemistry method used was a compound named BDM14950.55 
  
 
  
Figure 2.9 | BDM31381 and two analogues. Sixty different aliphatic and aromatic alkynes were chosen for 
their potential ability to interact with the hydrophobic portion of the EthR ligand-binding channel. They 
were sub-divided into six groups of 10 in such a way that condensation reactions between the component 
alkynes would result in combinations with different molecular weights. BDM14801 (125µM) was 
incubated with each of these alkyne groups and EthR (5µM) for five days at 37°C. The predominant 
product formed was named BDM14950 and co-crystallised with EthR (PDB: 3O8H).55 
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Willand et al. found that the area around the aperture of the ligand-binding channel is 
structurally conserved, but the upper part of the pocket is able to undergo structural 
rearrangement upon ligand binding. The ligands were seen to occupy equivalent 
positions, but for the longer ligand BDM14950, movement of two phenylalanine 
residues (Phe114 and Phe184) led to the opening of a ‘secondary pocket’ to 
accommodate the phenyl-iodide group (figure 2.10).  The crystal structure of EthR 
bound to BDM14950 confirmed the compound’s ability to induce the inhibitory 
conformation, but the variability of the structures to induce this inactive state 
necessitates further study 55. 
 
 
Figure 2.10 BDM31381 (left panel, PDB: 3G1M), BDM14801 (middle panel, PDB: 3O8G) and BDM14950 
(right panel, PDB: 3O8H) in the ligand-binding channel of EthR. BDM31381 and BDM14801 the lower 
portion of the pocket where the residues are structurally conserved, and the phenylalanine residues retain 
similar positions. However, BDM14950 is longer and to incorporate the phenyl-iodide group, Phe114 and 
Phe184 rotate to open up this auxiliary pocket. All three compounds share common equivalent positions. 
 
2.2.9 | Structural modifications to the inhibitors 
The investigation into the flexibility of the ligand-binding channel was not limited to 
simply extending the ligand as far as possible. Different terminal groups were 
introduced to determine if these could increase binding affinity or induce 
conformational change more readily. One of these modifications was the introduction 
of CF3 groups. 
 Fluorinated groups added to the BDM31381 analogues were shown to have a 
similar potency to the parent molecule and an increased solubility, but at a cost to the 
overall stability of the inhibitor. There was a steric limit to the number of fluorine 
atoms able to fit in this upper portion of the channel, however, and it was suggested 
that the fluorine additions were an aid to penetrance into the cell and not to the binding 
 
 
 
 
20 
of the protein target 56. This ability of fluorine to improve cell permeation in drug-like 
molecules has been seen in other areas of drug design and optimisation.57,58 
 The structural modifications in the ligand-binding channel shown in figure 2.10 
are made to accommodate a longer ligand. This requires flexibility of the target protein; 
here there is a weak, but proven, influence of the ligand upon the protein structure. If 
this can be taken into account, classical computational docking methods would give 
some insight into the potential of a drug to bind the target. However, docking 
simulations have a high computational demand. The speed of the simulation and the 
time taken can only be reduced with the imposition of limits on the model. These 
simulations also require three-dimensional co-ordinates of both the ligand and the 
protein, which can only be derived crystallographically. In this case, there are eight 
published structures of EthR in ligand-bound conformations (to date, with four as yet 
unreleased by the PDB, and one EthR mutant structure unreleased) which can be used, 
provided the ligand structures can be solved separately. If this were possible, 
crystallisation of the ligands alone would inform the drug design process without the 
need to co-crystallise with the protein. In cases where this co-crystallisation proves 
difficult, computational methods could be a boon to the drug design process. 
 
2.2.10 | In vitro and in vivo testing of EthR Inhibitors 
Various biological assays have been used to demonstrate and evaluate the effect of 
these designed EthR inhibitors in vitro and in vivo. Once BDM14500 had been 
crystallised with EthR and shown to inhibit the EthR-DNA interaction, the compound 
was tested for the ability to prevent Mtb H37Rv growth on solid agar plates.  
 
Figure 2.11 | The ability of Mtb H37Rv to survive on solid agar was tested in the presence of ETH with and 
without BDM14500. (Adapted from Willand et al., 2009)9 
 
Figure 2.11 shows the radial diffusion experiments performed with ETH and 
BDM14500. The radial diffusion experiments showed BDM14500 was not bacteriotoxic 
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alone, and instead had a synergistic effect with ETH. Therefore, BDM14500 analogues – 
which would also have this effect – were assessed for their pharmacological properties, 
as potential trial drug candidates. 
 
Figure 2.12 | Chemical structures of BDM31381 and BDM31343 
 
SPR assays revealed that BDM31381 was more potent in inhibiting EthR binding DNA, 
with a half-maximal inhibitory concentration (MIC) of 522-nM (the half-MIC of 
BDM31343 was determined to be 3.3-µM). As the more potent of the two inhibitors, 
BDM31381 was used to quantify an effect on ethA transcription in M. bovis BCG; the 
level of ethA mRNA in cultures treated with BDM31381 were compared with an 
untreated culture, and 20-nmol BDM31381 was seen to effect a 35-fold increase in ethA 
transcription. 
 Once the inhibitors were shown not to be cytotoxic up to 30-µg-ml-1 in human 
hepatocellular carcinoma cells - a model system for liver cell function - testing moved 
on to the mouse models. In mouse hepatic microsomes, the in vitro plasma half-life of 
BDM31381 exceeded seven days; for BDM31343 this was only 53 hours. Their 
respective solubilities in PBS were determined to be within a suitable range for 
intraperitoneal and oral administration and BDM31343 was seen to have a faster 
intrinsic clearance.9 
 To determine a basic in vivo pharmacokinetic profile of the two inhibitors, male 
CD-1 mice uninfected with Mtb were given a single intraperitoneal administration of 
either BDM31381 or BDM31343, dissolved in DMSO and at a dosage of 100-mg per kg 
of body weight. The integrated concentration-time curves show mice were exposed to 
concentrations of BDM31343 (82-µg-h-ml-1) exceeding the 7.5-µg-ml-1 required to 
boost ethionamide in vitro, but not sufficient concentrations of BDM31381 (5-µg-h-   
ml-1). Therefore BDM31381 was the most potent inhibitor in vitro, but BDM31343 
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possessed a superior in vivo pharmacokinetic profile. Therefore, both inhibitors were 
taken forward into mice with an active Mtb infection. 
 Male CD-1 mice, as used for the initial pharmacokinetic profile, were infected 
with Mtb and the disease was allowed to progress unhindered for seven days. Mice lack 
the CD-1 ‘group 1’ subset of the CD-1 family of glycoproteins. These molecules are 
present on antigen-presenting cells, and the group 1 subset are shown to favourably 
present foreign lipid antigens and those of mycobacteria; without them, an immune 
response is prevented. Therefore, CD-1 mice are a good model infection organism for 
TB and other mycobacterial pathogens.59 
 After seven days, mice were left untreated, treated with ETH only, or treated 
with ETH in combination with either BDM31343 or BDM31381. Mice treated with 
ETH/BDM31381 showed only a minor reduction in the bacterial load compared to the 
mice undergoing ETH-only treatment. However, mice treated with ETH/BDM31343 
showed a reduction in bacterial load as efficiently as a three-times-higher dose of ETH 
alone throughout the three-week treatment; administration of a 9 or 27-mg-kg-1 body 
weight dose of ETH was as effective as a 3 or 9-mg-kg-1 body weight dose of ETH in 
combination with BDM31343.9  
 This was in vivo proof of concept, demonstrating the effect of EthR inhibitors on 
ETH efficiency. The next step was to optimise the inhibitor design, which can be done 
through biological assay as well as structural studies. Co-crystal structures of a select 
few of the compounds have been published; however the lone crystal structures of 
these inhibitors had not been solved. The inhibitor crystal structures without a protein 
present can provide a wealth of information in regards to the conformation of the 
inhibitor, the potential sites for intermolecular interaction, and can be exploited for 
computational studies which can save time and resources.  
 
2.2.11 | Project Aims 
In this project, it was my intention to crystallise a selection of these inhibitors to 
determine their conformation in three-dimensions to high accuracy, and use this to 
confidently infer protein-ligand binding information; these inhibitor structures would 
also be used as a starting point for molecular docking. Due to the limited amounts of 
inhibitor available, crystallisation would prove challenging; however the information 
from structure solutions and docking analysis would inform further, more effective 
inhibitor design.  
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2.3 | An Introduction to X-ray Crystallography 
Crystallography is defined by the International Union of Crystallography as “the branch 
of science devoted to the study of molecular and crystalline structure and properties” 
(IUCr). X-ray crystallography is the method by which the pattern of diffraction of X-rays 
through a crystal is used to determine the molecular structure in three-dimensional 
space. This section will give a brief, qualitative overview of how the diffraction pattern 
of a crystal can lead to a structure solution and the underlying physical principles.61 
  
2.3.1 | X-ray Diffraction by Crystals 
To relate a crystal to its diffraction pattern, various concepts have to be explained. 
Chapter 3 will describe how crystals are formed; suffice to say at this point that the 
individual molecules of the crystal align in identical conformations, held by 
intermolecular interactions, creating a repetitious pattern. In any three dimensional 
repeating pattern, there is a small section that, if defined and if any symmetry or 
translation elements are assigned, can be used to describe the entire pattern. In the 
case of a crystal, this is the unit cell.  
 
 
 
 
 
 
The unit cell may contain one or more, or a fraction of a molecule, depending upon the 
internal symmetry and how those molecules relate to each other in three-dimensional 
space. Therefore, a crystal is made of repeating unit cells, defined by three lengths (in 
Å; 1 Å is equivalent to 10-10m) and three angles (in degrees). There are seven crystal 
systems based upon the geometry of the unit cell (figure 2.13); the descriptions of 
Figure 2.13 | A schematic of a unit cell, showing the three axes (a, b and c) and the three angles (α, β, γ). 
The classifications on the right denote the geometric qualities of the unit cell, however certain internal 
symmetries must be satisfied in addition to the axes lengths and angles. For example, a monoclinic cell 
must have a two-fold rotational symmetry; though trigonal and hexagonal have the same geometric 
qualities, a trigonal cell has a three-fold rotational symmetry where a hexagonal has a six-fold. 
Triclinic: 
no unit cell restrictions 
a ≠ b ≠ c ; α ≠ β ≠ γ 
 
Monoclinic: 
α = γ = 90° 
 
Orthorhombic: 
α = β = γ = 90°  
 
Tetragonal: 
a = b ; α = β = γ = 90° 
 
 
 
 
Trigonal: 
a = b ; α = β = 90°; γ = 120° 
 
 
Hexagonal: 
a = b ; α = β = 90°; γ = 120° 
 
Cubic: 
a = b = c ; α = β = γ = 90° 
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translation and symmetry operations which relate the contents of the unit cell to the 
entire crystal give 230 crystallographic space groups, each with a distinct notation to 
define those operations. 
 
2.3.2 | The crystal lattice 
All of the descriptions so far have been in real space, however to relate the crystal to 
the diffraction events, mathematical constructs are used. The first of these is the crystal 
lattice.  
 If each unit cell in the crystal was to be represented as a point rather than a 
constructed box containing atoms, then a three-dimensional lattice of points would be 
formed. The spacing between these points depends upon the geometry of the unit cell – 
a longer unit cell will show a more widely-spaced lattice. Lines can be drawn through 
the points in two dimensions, and in three, these become lattice planes (figure 2.14). 
 
Figure 2.14 | Lattice points to lattice planes. 
 
A reciprocal lattice is derived from the dimensions of the ‘direct’ crystal lattice, and it is 
the reciprocal lattice that is seen in a diffraction pattern. The reciprocal lattice is 
measured in distances of Å-1 and degrees and as such, long spaces between lattice 
points become small spaces between reciprocal lattice points; wide distances of d on 
the lattice become small distances of d-1. The reciprocal lattice is put into use to 
describe a diffraction event through Bragg’s Law.  
  
     2  sin  
Equation 1 Bragg’s Law states that constructive interference of waves will occur when the path difference 
between two incident waves is equal to the wavelength multiplied by an integer: n  = 2d sin . 
 
Constructive interference is a requirement for measurable diffraction; diffraction by a 
single atom of a molecule is too weak, and so the constructive interference of diffracted 
waves by identically positioned atoms in the crystal magnifies the signal. Therefore, 
diffraction is described as reflection by lattice planes. 
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Figure 2.15 (a) shows the principle behind Bragg’s Law. Incident waves diffract from identical points on 
different planes. (b) depicts two waves out of phase, with the same frequency and wavelength; their 
amplitudes sum to zero. (c) shows the opposite: two waves in with the same phase and frequency, which 
combine to create a wave with an amplitude equal to the sum of the amplitudes of the constituent waves. 
 
2.3.3 | Miller Indices 
To define planes in a crystal and describe complicated crystal shapes, Miller Indices are 
used. They were introduced as a notation in the early 1800s, but developed and 
published in 1839 by WH Miller, then the Chair of Mineralogy at Cambridge 
University.62 To assign the indices, axes are chosen so that the axes x, y and z align 
respectively with the unit cell axes a, b, and c. The Miller indices - h, k and l – are always 
integers (figure 2.16). Planes can be defined by Miller Indices by 1/ha, 1/kb and 1/lc, 
thus defining the reciprocal lattice. 
 
 
  
Figure 2.16 | Where the plane intersects the 
unit cell axes, fractional co-ordinates are 
assigned, such that the plane that intersects x 
at a/h, y at b/k and z at c/l. Therefore, the 
plane is defined as h, k and l, or hkl. 
Here, axis x is intersected by the plane at ½, 
axis y at 1 and axis z at ⅓. 
Therefore, this plane is defined as 213. 
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2.3.4 | Combining Waves to Give An Image of Electron Density: The Phase Problem 
When diffracted waves intercept the detector, they are recorded as intensities; the 
intensity is proportional to the square of the amplitude of the wave (figure 2.16), but 
the phases of those waves are lost.  
 
Figure 2.17 | The geometry of a periodic wave. 
 
Euler’s formula establishes the relationship between trigonometric functions (as used 
to describe periodic waves) and complex exponential functions (as used to calculate 
electron density). This formula can be seen as equation 2, below. 
 
e    co    i  in  
Equation 2 | Euler’s formula, where ‘e’ is the exponential function,  
‘i’ represents an imaginary number, and ‘ϕ’ is the angle given in radians. 
 
To relate diffracted waves to the electron density and so solve the crystallographic 
structure, a Fourier transformation is used (equation 3). Euler’s formula is used to 
encompass the cosine and sine functions of the diffracted waves into the notation using 
2πi. However, it is not as straight-forward as simply solving the resulting equation; we 
must take into account the structure factors. Structure factors describe the amplitudes 
and phase of each spot on the diffraction pattern, but the phases have been lost in the 
course of our diffraction experiment – this is the phase problem. 
 
  
Equation 3 | Structure factors (red) are related to the electron density at each point in the cell (green) by 
integration. Reciprocal space and real space must be reconciled using a complex term (blue). 
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Without the phases, only the observed amplitudes can be used. As F(hkl) is a complex 
number, with an angle and length, we can consider the phases as the angle ϕhkl and the 
length (or amplitude) as |F(hkl)|; we arrive at equation 4 for the electron density. 
 
Equation 4 | The amplitudes (red) and phases (grey) of all diffracted waves are summed (and adjusted to 
relate real and reciprocal space, blue) to determine the electron density (green). 
 
However, the electron density still cannot be calculated without the phase information 
(the grey term in equation 3). Therefore, structure solution requires solving the ‘Phase 
Problem’. 
 
2.3.5 | Solving Structures in Chemical Crystallography 
There are various methods in chemical crystallography to solve small molecule 
structures, involving different approaches to the phase problem. The first and oldest of 
these methods is known as ‘trial and error’ and was particularly useful in the early days 
of X-ray crystallography where structure solutions were attempted upon simple 
structures with only a few parameters. 
 The trial and error method begins with assigning a chosen reflection the 
structure factor F(000); this is then used as a reference point to calculate the places of 
the other atoms. A trial structure can then be tested for accuracy by calculating an R 
factor (equation 5). 
R = 
   Fo     Fc  
     o  
 
Equation 5 | The reliability index for trial structures, comparing calculated structure factors (Fc) and 
structure factors derived from observed intensities (Fo). The R factor is minimised during solution to an 
agreement between the observed and calculated structure factors. 
 
The lower the value of R, then the more similar the calculated and experimental 
structure factors are, making the trial structure more likely to be correct; when this is 
the case, the trial structure can then undergo refinement. If the R value shows the 
structure factors differ greatly, then the process is taken back to the beginning and a 
different F(hkl) position is used. This method can be powerful where there are many 
constraints upon the crystal packing; for example, high symmetry space groups where 
atoms must occupy special positions to satisfy all symmetry operations. However, this 
is a very inefficient method of structure solution, when the origin could lie at one of 
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many positions of F(hkl) within the crystal, particularly in low symmetry space 
groups.63 
 A second method, suggested in 1934, is the Patterson method.64 Until this point, 
trial and error had been the only way to solve chemical crystal structures. The 
Patterson method relies upon the presence of a notably heavy atom within the 
structure, and takes advantage of known inter-atomic distances. The Patterson function 
is a Fourier series which does not require phase information (equation 6). 
 
Equation 6 | The Patterson function, whereby P(x, y, z) will have a peak which  
corresponds to each inter-atomic vector in the structure.64 
 
 i =  i     i     i  
Equation 7 | Defining the position of an atom in a Patterson function. 
 
If each position is defined as ri (according to equation 7), then the Patterson function 
gives peaks ri – rj, where i is 1 and j is the number of atoms in the unit cell. The total 
weight of the peak will be the sum of the two atomic numbers of the two atoms forming 
the vector. The highest peak will be the vector between the heaviest atom and itself at 
an equivalent position; as a vector will be created between every atom in a cell, a unit 
cell containing n atoms will give nn-1 Patterson peaks. By picking vectors carefully and 
using the atomic numbers of constituent atoms carefully, atoms can be assigned to each 
vector and so each electron density peak; heavy atoms make this particularly easy, as 
the vectors are distinguishable from those between lighter atoms, allowing the heavy 
atom to become a reference point. This is a powerful method, still in use and 
development after nearly seventy years, however it is not applicable to this project, as 
none of the compounds in question contained sufficiently heavy atoms to make this 
method a viable option.64 
 The most widely utilised method of structure solution today is direct 
methods.65 Direct methods are an ab initio approach requiring two assumptions; first, 
that the electron density will only be positive where atoms are present (thus zero 
elsewhere) and second, that the structure consists of point-like atoms. With these 
assumptions, normalised structure factors calculated from the observed amplitudes 
can be used in the place of the unaltered observed values; these are |E| values rather 
than |F|. Only high |E| values are used to contribute to the electron density map, 
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ensuring that the most positive areas are included, and it logically follows that these 
strong positive areas of electron density are point-like atoms.66 
 Next, a limited number of phases are assigned to those Bragg reflections which 
are probably equal, known as ‘triplets’.65 The probability of these phase relationships 
giving a positive electron density is calculated. Only the best set of phases (ie. the most 
correct, positive set) is used to calculate the electron density map, with |E(hkl)| taking 
the place of |F(hkl)| in equation 3. Once atoms are assigned to the resulting electron 
peaks, the phases undergo refinement to arrive at the final structure.63,67 
 
2.3.6 | Refining Structures in Chemical Crystallography 
Refinement is the adjustment and optimisation of the parameters in the crystal model, 
defined by the atomic co-ordinates obtained in the structure solution. As the sine and 
cosine functions of the Fourier series for calculating the electron density are not linear, 
crystallographic refinement makes use of non-linear least squares regression. This 
method depends on over-determinancy in the model, and small molecule structures 
generally require a data-to-parameter ratio of 10:1 or more, meaning 10 Bragg 
reflections for every parameter. Parameters for refinement include (but are not 
necessarily limited to, depending on the nature of the model) the atomic coordinates (x, 
y, z) and atomic displacement parameters (ADPs are described below). The refinement 
indicators are two R-factor statistics, R1 and wR2.68 
 Least squares (in a non-linear form) is derived from the Taylor series and 
differs slightly depending upon whether the parameters are being refined against F or 
F2. SHELXL refines against F2, utilising equation 8. Refinement against F2 has 
advantages over refinement against F, which can result in mathematical problems with 
weak reflections or intensities with negative measurements. Refinement against F2 is 
not subject to these issues, and so reduces the possibility of the refinement stalling in a 
local minimum. With F2, all data can be used with appropriate weighting; the weighting 
is determined by experimentally-derived standard deviations. 
 The atomic positions and thermal factors for each atom in the structure are 
derived from the initial model, giving Fcalc (Fc). 
 
 (Fo2 – Fc2)
  
        Fo2   Fc2)Fc 
 Fc
  
 
Equation 8 | The least squares refinement equation used by SHELXL.69 
 
Fo represents the experimentally observed structure factors, while Fc represents the 
calculated structure factors from the model and subsequent refinement. While Fo 
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carries random errors and systematic experimental errors, Fc carries no errors. What 
follows is an iterative refinement of Fc from Fo with corrections, until they converge to a 
global minimum. Theoretical R-factors represent the difference between the observed 
and calculated structure factors; as the refinement progresses, the R factors should fall. 
A good R1 factor for a small molecule in chemical crystallography is 5% or below. 
 
R = 
    Fo     Fc )
   o 
 
Equation 9 | The R1 factor is the clearest and most reliable of the two refinement indicators.70 
 
wR2 = 
 w(Fo2 – Fc2)2
 w  o2 2
 
Equation 10 | wR2 uses squared factors, increasing the value by up to 3x that of R1. This value is the one 
actually minimised by least squares, but R1 is more conventionally used to compare refinements as it is 
less dependent on weighting and is easier to understand.69 
 
The wR2 factor is typically greater value than R1 as it uses squared factors. It is also 
subject to a user-adaptable weighting scheme and so R1 is considered a more reliable 
refinement indicator.70 
 As the refined model begins with values determined from the structure 
solution, the starting data must be good, with atomic positions correct to within 0.5 Å. A 
poor starting model is just one of the issues which can cause refinement to fail; a poor 
understanding of how to handle the data can lead to the same failure. For example, data 
from poor quality crystals with low resolution will not have the accuracy to determine 
the atomic co-ordinates accurately. A chemical understanding is required to recognise 
disorder, whether in the structure of in the solvent, as well as correctly impose any 
restraints or constraints on the model to improve the refinement. Similarly, including 
spurious atoms can incorrectly inflate the anisotropic displacement parameters – 
ADPs.69  
 ADPs, often represented as 50% probability ellipsoids, represent the dynamic 
disorder, where vibration causes movement, and static disorder, where slightly 
differing atomic positions between unit cells cause the electron density to show a shape 
other than perfectly spherical. Extended ADPs may indicate disorder or the omission of 
a neighbouring atom in the structure.71 
 While the refinement is built upon a straight-forward and clearly defined 
principle, a great deal of user understanding and interpretation is required to ensure a 
successful result. This requires various standards to achieve a good data set to a high 
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resolution (for small molecules, ideally better than 1 Å), with a well-defined starting 
model, for example a high data-to-parameter ratio (ten or greater) and diffraction data 
collected at lower temperatures to minimise thermal motion and radiation damage.  
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CHAPTER 3 
METHODS 
3.1 | Introduction to the crystallisation of small organic compounds 
The benefits of crystallisation in structural studies have been described in the previous 
chapter; in practice, crystallisation of organic compounds can prove time-consuming 
and technically demanding. This section will introduce the kinetic and thermodynamic 
principles behind crystal formation as well as describe the methods frequently used in 
crystallisation to generate single crystals for X-ray diffraction studies. 
 Solution methods, by which the solid compound for study is crystallised from a 
solvent, are the most flexible methods when attempting to grow good quality crystals.  
The wide selection of potential solvents, alone or in combination, make for a dynamic 
set of possibilities to choose from. The aim is to bring a concentrated homogenous 
solution to the point of supersaturation, where it can then relax into the metastable 
zone (figure 3.1). This increases the likelihood of nucleation and the formation of a 
single, ordered crystal.72 
 Crystal formation is a two stage process. First, nucleation must occur, followed 
by sustainable crystal growth. Nucleation is a stochastic, localised phase change from 
solution to solid, in which a small number of identically oriented molecules associate to 
form a regularly ordered cluster.73 This event can occur once in a solution, or multiple 
times depending upon various factors including (but not limited to) the concentration 
of the solution, the temperature, and the degree of manual disturbance to the solution. 
Once the initial nucleation point has been reached, molecules of the compound which 
are in the correct, identical orientation can be adsorbed to the surface of the critical 
nucleus; thus a crystal is formed and grows. This allows the system to relax to a 
thermodynamic equilibrium, and the main growth phase of the crystal takes place in 
the metastable zone (figure 3.1). 
 If crystals grow too quickly, there is a risk of constituent molecules misaligning, 
leading to disordered crystals or in more severe cases, multiple crystals growing 
together. This would render them useless for analysis by X-ray diffraction, as single 
ordered crystals are essential. Alternatively, an under-saturated solution can lead to 
nucleation sites disassociating, preventing crystal growth. Intermolecular interactions 
between molecules of the compound will support the crystal packing structure and 
stabilise the formation and growth process. In organic molecules, the most common 
interactions are hydrogen bonds, electrostatic interactions and hydrophobic 
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interactions; however, when present, metal co-ordination and solvent-mediated 
contacts are another strong determinant of crystal packing 74. Therefore, the 
occurrence of crystal formation and the rate of crystal growth are unpredictable. 
 
 
Figure 3.1 | Phase diagram of crystallisation with a solvent in which the compound is moderately soluble. 
The relative concentrations of the compound and crystallising agent (solvent) determine solubility. If 
supersaturation can be reached beyond the solubility curve (solid black line), nucleation and initial crystal 
growth will occur in the nucleation zone. As growth continues, the concentration of compound decreases 
and the main growth phase continues in the metastable zone. With increased solubility of the compound in 
the solvent, the solubility curve moves to the right, making supersaturation harder to achieve. 
 
The degree of solubility of the compound in the chosen solvent is important to crystal 
formation, dictating how quickly a saturation point can be reached with a given amount 
of material. Generally, a compound will be most soluble in a solvent which is chemically 
similar; if functional groups or polar moieties of the compound are known, this 
information can be used to choose a solvent with similar characteristics.  The best 
solvent for growing single crystals of suitable size for x-ray diffraction studies is one in 
which the compound for study is moderately soluble. If the compound is exceptionally 
soluble in a solvent, any micro-crystals formed at nucleation will re-dissolve, 
preventing crystal growth; if the compound is barely soluble, there will not be enough 
dissolved material to form crystals at all. For this reason, the first step taken in 
attempting to re-crystallise my samples was always an initial solubility screen against a 
library of solvents.75 
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3.1.1 | Method: Initial Solubility Screens 
After initial observations on the nature of the sample were made under a microscope 
(such as colour, habit, if the sample was crystalline or not, if any crystals could be seen 
in the sample from which predictions on the eventual crystal shape could be made), 
solubility screens were carried out on a standard microscope slide, with up to 5-µl of 
solvent and a small amount of the compound for study. 
 
 
Figure 3.2 | When performing a solubility screen, the slide is labelled to keep track of the results (seen in 
the photograph a, and the schematic b). The coloured circles denote different solvent drops with the 
powdered compound distributed through the slide. I developed a convention by which my first, far left 
solvent drop would be water, with the subsequent drops of organic solvents (beginning with acetonitrile 
and toluene, ending in DMF and DMSO) increasing in boiling point. 
 
Each solvent was added to the slide using a 2-200-µl pipette, and the powdered 
compound was added to the solvent drop using a clean needle. Observations under the 
microscope on the relative solubility of the compound in each solvent were made, 
including any additional observations: for example, if the powder broke apart in any 
specific manner. For example, if the powder appeared to ‘splinter’ apart, this could 
indicate the presence of needle-shaped crystalline material in the powder, and this 
suggests crystallisation may occur in this form. 
 
3.1.2 | Theory: Crystallisation by Evaporation 
The evaporation of the crystallisation solvent brings the system into supersaturation in 
the metastable zone, where nucleation can occur. However, since evaporation is an 
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open system, there are many conditions affecting the experiment. This makes 
evaporation difficult to reproduce. For the organic solvents in the library with 
comparatively high boiling points (such as DMF, DMSO and NMP, show in figure 3.5), 
initial evaporation experiments were carried out on the solubility screen slide. 
 If an evaporation experiment cannot be performed on the screen slide, or the 
experiment bears repeating, it is preferable to do so in a watch glass or glass 9-well 
plate, or a suitable glass vial (specific protocols used for acquiring my crystals are 
described in sections 3.1.6 – 3.1.11). The glass should be clean, with an aperture wide 
enough to facilitate removing small crystals; the vial can be stored at an angle to 
encourage crystals to grow on the side of the vial to make crystals easier to harvest. 
The vial can be left uncapped, or a perforated cap can be used to slow the rate of 
evaporation of volatile solvents. 
 The most undesirable result in an evaporation experiment is for the 
solvent/compound mixture to evaporate completely without crystallisation. Such failed 
crystallisation could occur because the solution was under-saturated and did not reach 
a nucleation point, or due to a misjudged solvent-to-compound ratio. Where there is 
enough material available, varying this ratio may bring the system to supersaturation; 
however, with limited material (ie. less than 8-10 mg), experimenting with different 
conditions can potentially waste material on an unsuitable solvent. Therefore, if under-
saturation due to the high solubility of the compound in the chosen solvent is 
suspected, an alternative solvent is the preferable choice. 
 Crystallisation may fail because of poor and transient intermolecular bonds at 
the nucleation stage. While a nucleation point may have been reached, it is possible 
growth is prevented because the molecules of the compound were simply unable to 
remain in an identical conformation long enough to find a stable and sustainable 
growth phase. Altering the temperature or the speed of evaporation is the most 
effective way to encourage sustainable crystal growth. As such, evaporation 
experiments (and diffusion, described below) were often repeated in a refrigerator at 
4°C.  
 When evaporation techniques failed, as they did for the protonated peptoid 
precursor form and BDM41325, diffusion techniques in sealed vessels were my next 
step. With a sealed vessel, more control is gained over the conditions of the 
crystallisation experiment. 
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3.1.3 | Theory and Method: Crystallisation by Liquid Diffusion 
Evaporation techniques can fail for a number of reasons, not least that the solubility of 
the compound in a chosen solvent is too high and supersaturation cannot be reached. 
To reduce this, anti-solvents can be used. By definition, anti-solvents are solvents in 
which the compound is not (or is barely) soluble; such anti-solvents would have been 
identified in the initial solubility screen for each compound. Using solvents in this 
combinatorial fashion alters the solubility of the compound, lowering the 
supersaturation point and theoretically making nucleation and sustainable crystal 
growth easier to achieve. 
 Liquid diffusion involves creating an interface (figure 3.3) between two 
solvents; one in which the compound is soluble, one in which the compound is not.76 
 
Figure 3.3 | The compound (~0.2 mg) is dissolved in a small volume (≤100 µL) of solvent A (1 and 2), in 
which it is moderately soluble. The anti-solvent, ‘solvent B’ (3) should be added to the vial in such a way as 
not to mix with the solvent-compound mixture. Solvent to anti-solvent ratios of 1:2, 1:3 or 1:4 were 
typically used. This can be achieved by adding the anti-solvent dropwise down the side of the glass vial. As 
solvent B will be less dense than solvent A, layers should form. Seal the vial and leave undisturbed in a 
stable temperature environment for a few hours to a day or two. If successful, crystals will form in the 
concentration gradient of the diffusion zone formed by the interface of the two solvents (4). 
 
The key to liquid diffusion is the difference in solubility between the two solvents. 
Solvent A should provide moderate solubility for the compound for study, just as would 
be used in an evaporation experiment; if liquid diffusion is being used because no 
solvent has been found to fit this criteria, solvent A must be one in which the compound 
is soluble, and a stronger anti-solvent (solvent B) can be used. While the two solvents 
should be miscible, they should have distinct densities. The aim is to create a diffusion 
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zone (seen above in 4 as a green band between the two solvents) where the two 
solvents are in contact and have a limited interaction; if they are too similar in their 
densities and volatility, the two solvents will mix too thoroughly. An ideal ratio of 
solvent A to solvent B is around 1:4, but this method is versatile. If the compound is 
readily soluble in solvent A, more anti-solvent will be required; if the initial volumes do 
not yield crystals, it is quite straight-forward to remove the cap and add more anti-
solvent, taking care not to disturb the solutions too much and cause over-mixing. This 
was of particular advantage to me, having a finite supply of material to work with – the 
solution can be cooled, or even heated and then allowed to cool to room temperature, 
in an effort to encourage nucleation. As evaporation of the compound-solvent mixture 
is not allowed to occur, none of the compound is lost and the experiment can be altered 
and repeated easily.  
 Even with appropriate solvent choices, this method can (and does) fail. For 
example, if the system is not closed – if the vial is not completely sealed – the volatile 
anti-solvent will evaporate and will not aid in crystallisation. If the experiment is stored 
somewhere with a fluctuating temperature, or which is not still and free from 
movement or tremors, a nucleation point will be more difficult to reach. Crystals will 
take up to a few days to form and grow, even at low temperatures where energy and 
movement of the molecules is restricted. Manual disturbance should be avoided so a 
stable, dry and ideally temperature-controlled storage place should be chosen, and the 
experiment should not be removed to be checked frequently – this method is slow 
enough that daily observation should be sufficient.  
 In the event that the only anti-solvent found for the compound is denser and 
less volatile than the solvent in which the compound is soluble, there must be an 
alteration to this method. For example, if the compound was soluble in acetonitrile, but 
not soluble in water, the water fraction can be layered on the bottom of the vial, and a 
mixture of acetonitrile and the compound can be carefully added to make the top layer. 
This would make it impossible to add more anti-solvent should crystals not form, but 
does further demonstrate the usefulness and versatility of anti-solvent/solvent 
mixtures. 
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3.1.4| Theory and Method: Crystallisation by Vapour Diffusion 
Vapour diffusion is a technique typically used for the growth of single crystals of 
peptides and proteins, using similar principles to liquid diffusion. However, where 
liquid diffusion works best with high compound concentrations, vapour diffusion can 
handle comparatively smaller amounts of sample (ie. ~0.2 mg) and multiple 
experiments can be run in the same environment at one time. This gives a greater 
through-put to the experiment and can yield multiple crystals. Vapour diffusion is also 
slower, which should result in single, more ordered crystals for diffraction 
experiments. Figure 3.4 shows a basic schematic of a vapour diffusion experiment. 
  
  
Figure 3.4 | Vapour diffusion involves two vessels, one placed inside the other, where the volatile anti-
solvent (‘solvent B’ in 3 and 4) is allowed to diffuse into the solvent-compound mixture. First, a small 
amount of compound is dissolved into a solvent (≤100 µL) in which it is moderately soluble, just as in 
evaporation and liquid diffusion experiments (2) in a small vessel. This vessel is placed inside a larger 
vessel, uncapped, filled with a volume of the anti-solvent (3) typically at a 1:3 or 1:4 ratio. This larger 
vessel is then capped. The volatile anti-solvent diffuses into the smaller vessel, reducing the overall 
solubility and inducing supersaturation. 
 
As with liquid diffusion and evaporation, solvent choice is key, and solvents suitable for 
liquid diffusion will work for vapour diffusion in a similar way. The anti-solvent ought 
to be more volatile than the solvent, however in this case the degree of difference is not 
as crucial as with liquid diffusion. As long as the anti-solvent will diffuse into the 
solvent-compound mixture, this technique can be successful (meaning the anti-solvent 
must be the more volatile of the two, otherwise a volatile solvent will diffuse into the 
less volatile anti-solvent, leaving a decreasing solvent-to-compound ratio: this is 
essentially evaporation in a closed system). Whichever technique is used, sustained 
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nucleation events are serendipitous, and any method utilised is simply an attempt to 
make nucleation more likely.  
 
3.1.5 | Method: Crystallisation of an anionic peptoid precursor 
Crystalline material of an anionic peptoid precursor was provided for analysis, grown 
by slow evaporation of acetonitrile at room temperature in a glass vial. Long, thin and 
fragile single crystals were formed on the sides of the glass. 
 
3.1.6 | Method: Crystallisation of a protonated peptoid precursor 
Initial attempts were made to grow crystals of the 5 mg of protonated precursor 
compound (a white, crystalline powder) by evaporation. The compound was found to 
be soluble in ethanol, acetonitrile, DMF and DMSO, and the compound would re-
crystallise at room temperature and at 4°C readily from both DMF and DMSO. However, 
nucleation was rapid and abundant; crystals grown by evaporation from these solvents 
were invariably long, thin and fragile – too small for analysis (ie. thinner than 10 µm in 
two dimensions).  
 Liquid diffusion techniques were used in an effort to control this rapid crystal 
formation with anti-solvents; the protonated peptoid precursor was observed to be 
insoluble in water and toluene. No crystals formed from the DMSO or DMF liquid 
diffusions with either of these anti-solvents after two weeks and so the solutions were 
allowed to evaporate; crystals of the similar poor quality were formed and under closer 
inspection, what appeared to be long single crystals were in fact multiple crystals 
growing side-by-side in succession.  
 Evaporation of 100% ethanol did not yield crystals, nor did evaporation of 
acetonitrile. Liquid diffusion experiments of ethanol/water and acetonitrile/water at 
1:2 ratios were set up with the remainder of the sample but none were successful in 
forming crystals. The caps sealing both liquid diffusion experiments were removed and 
the solutions were mixed and heated, then finally re-sealed. The cooling of the mixed 
solutions did not lead to sustained nucleation, and so the caps were removed and 
evaporation was allowed as a last effort to re-crystallise the molecule. Evaporation of 
the 50% acetonitrile solution did not yield crystals. 
 However, crystals were formed by the evaporation of the 200-µl 50% ethanol 
solution, in two distinct habits: needles and blocks. A small (200 µm x 100 µm x          
100 µm) clear, light, block-shaped crystal was used for X-ray diffraction analysis. 
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3.1.7 | Ongoing Crystallisation Attempts of Peptoid Precursor Molecules 
Two more peptoid-related molecules (of unknown chemical structure) are under 
investigation, but as yet no crystals of a sufficient quality for X-ray diffraction analysis 
have been achieved. Compound A is exceptionally soluble in DMF and quite soluble in 
DMSO, readily crystallising from the evaporation of both, and also soluble in 
acetonitrile and ethanol. Crystals formed from the evaporation of DMF and DMSO were 
thin and exceptionally fragile; though crystals derived from DMSO evaporation were 
marginally less fragile, they weren’t robust enough to use for analysis. Evaporation of 
both acetonitrile and ethanol at 25%, 50% and 75% did not result in crystal formation. 
Similar results were seen for Compound B.  
 Anti-solvents suitable for use on both samples included water, toluene and 
hexane. The liquid diffusion technique used with the protonated peptoid precursor was 
repeated for Compounds A and B without success – evaporation occurred without any 
re-crystallisation. Liquid diffusion and vapour diffusion experiments (of DMF/water, 
DMSO/water and ethanol/hexane) have not yet been able to slow the rapid crystal 
growth to yield larger and more robust crystals. Therefore, despite all efforts, no 
suitable crystals have been achieved from these two peptoid-related molecules. 
 
3.1.8 | Method: Crystallisation of BDM31343 
Crystallisation had been successful from a 20-µl volume of 100% dioxane, by seeding 
this solution in a glass well plate with small crystals formed in the initial solubility 
screen. However, these crystals did not diffract under X-ray analysis to a sufficient 
resolution (ie. less than 1-Å). Re-crystallisation was also attempted in NMP (figure 3.5, 
below). 
 
 
 
 
Figure 3.5 | Crystals of BDM31343 grown by evaporation of NMP (N-methyl pyrrolidone) at room 
temperature. Crystals formed in a drop on the initial solvent screen (left) were too small to use for x-
ray analysis and were instead used to seed a drop in a glass well-plate (right). These crystals are thin 
(estimated at ~10 µm) with poorly defined edges and are not suitable for diffraction experiments. 
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As seen with dioxane, the NMP initial solubility screen also resulted in the formation of 
small crystals; the crystals formed in 20-µl of 100% NMP in a glass well plate were of 
poor quality (figure 3.5). BDM31343 was observed to be soluble in DMSO, and crystals 
were grown by the evaporation of 20-µl 100% DMSO at room temperature in a glass 
well plate. 
 
3.1.9 | Method: Crystallisation of BDM41420 
As described above, the initial solubility screens involve spreading some of the 
compound across a slide. In the case of BDM41420, some of the powdered sample 
appeared to contain single crystals. Before commencing the solubility screen, four of 
these apparently-single, grey and block-shaped crystals were harvested. 
 In initial solubility screens, BDM41420 was seen to be soluble in polar, organic 
solvents such as ethanol, acetonitrile, DMF and DMSO. No crystallisation occurred on 
this screen slide, however, and so evaporation experiments were performed in glass 
well plates using 20-µl of DMF and DMSO at room temperature. These experiments 
were not performed on ethanol or acetonitrile because at room temperature, these 
solvents evaporate rapidly; with a limited amount of compound, it was preferable to 
use the solvents with the higher boiling points, allowing as much time as possible for 
nucleation and crystal growth to occur. 
 No crystals were formed from the evaporation of 100% DMSO, however needle-
shaped, clear crystals were formed through the evaporation of 20-µl 100% DMF at 
room temperature in a glass well plate. When screening these crystals on the 
diffractometer, they proved too small for diffraction analysis. The four crystals 
harvested from the original sample were screened; three diffracted poorly and the final 
crystal was not, in fact, single. However, the crystal was successfully cleaved to around 
half its size, and was subsequently used for diffraction study. 
 
3.1.10 | Method: Crystallisation of BDM41907 
BDM41907 was a white powder which appeared as a collection of small needles. These 
clusters were found to be soluble in ethanol, acetonitrile, DMF, DMSO. A thin, clear, 
needle-shaped crystal of this compound was grown in 20-µl 100% DMF in a glass well 
plate at room temperature. 
 
3.1.11 | Method: Crystallisation of BDM41325 
BDM41325 showed a similar solubility profile to the compounds crystallised before, 
seen to be soluble in ethanol, acetonitrile, DMF and DMSO, yet insoluble in water and 
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toluene. Evaporation from all solvents with the exception of DMF was unsuccessful. In a 
glass well plate, evaporation of 20-µl 100% DMF yielded small clusters of needle-
shaped crystals. In an attempt to slow nucleation, I set up a liquid diffusion of DMF and 
water at a ratio of 1:4, at room temperature. The same clusters were observed, though 
the clusters were larger than had been grown through evaporation. At that point, 
untried solvent combinations (including DMF/toluene, DMSO/water and 
DMSO/toluene) were used in an attempt to grow single crystals in isolation; this 
proved fruitless. Therefore, a thin paper taper was used to harvest the crystal clusters 
grown in the DMF/water liquid diffusion. The cluster was moved into a drop of inert oil 
on a glass slide (discussed later in section 3.2) and a large enough single crystal 
fragment was successfully separated from the crystal cluster for analysis by X-ray 
diffraction (figure 3.7 in section 3.2). 
 
3.1.12 | Ongoing Crystallisation Attempts of EthR Inhibitors 
At the beginning of this project, eight inhibitors were supplied, only four of which 
crystallised sufficiently to take forward to X-ray diffraction studies. The four remaining 
inhibitors are at various stages of investigation. 
 BDM41906 and BDM41281 are the least studied so far. Initial solubility screens 
on both showed solubility in acetonitrile, DMF, DMSO and ethanol, and insolubility in 
water. Evaporation trials of BDM41281 in these solvents have not led to any re-
crystallisation. BDM41906 was moderately soluble in DMF, but so far all evaporation 
and liquid diffusion experiments have led to precipitation. 
 The initial solubility screen on BDM41425 resulted in irregularly-shaped small 
crystals forming from the evaporation of 100% DMF. However, this could not be 
repeated in a glass well plate with varying amounts of compound. A liquid diffusion 
experiment of BDM41425 dissolved in DMF with toluene as an anti-solvent (a 1:3 ratio) 
resulted in the growth of tiny star-shaped clusters at room temperature. This was 
repeated in a vapour diffusion experiment in an attempt to slow the growth of crystals, 
and though crystals formed, they were no larger and arranged in the same clusters. 
Temperature variations have had no effect on the formation and growth of these 
crystals, and unlike BDM41325, these crystals are too small to separate one for 
analysis. 
 BDM41231 has undergone the most investigation of the four remaining 
inhibitors. The initial solubility screen showed a slightly different solubility profile, as it 
was soluble in toluene as well as ethanol, acetonitrile, DMF and DMSO. BDM41231 
demonstrated a tight meta-stable zone for nucleation and crystal growth.   
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 On the initial screen, thin crystalline ‘rafts’ formed on the surface of the DMF 
drop; disturbance of the drop with a needle caused these to aggregate. This was 
repeated in 1-µl and 3-µl drops of DMF on a separate clean slide (these volumes are too 
small to warrant using a glass well plate), but the same observation was made. 
However, in 20-µl DMF in a glass well plate, clear needles formed after a period of 90 
mins, but so rapidly that they began to adhere to each other and were impossible to 
separate, even when transferred to inert oil. Some of these aggregated needles were 
transferred to a new 20-µl DMF drop and re-dissolved; evaporation occurred without 
re-crystallisation and the original effect could not be repeated. BDM41231 dissolved in 
a 20-µl DMSO drop in a glass well plate led to precipitation in under an hour. With 
decreasing amounts of compound, re-crystallisation did occur, however in the first 
instance these crystals were thin, thread-like and aggregated almost like fibres, and 
with a further decrease in compound concentration, similar crystalline rafts as seen 
with DMF formed on the top of the drop. Liquid diffusions of ethanol/water and 
DMF/water were set up at 1:3 ratios at both room temperature and 4°C; no re-
crystallisation occurred. A DMSO/water vapour diffusion (1:4) at room temperature led 
to the formation of small clusters which were tightly inter-grown and impossible to 
separate. This final round of liquid and vapour diffusions consumed the last of the 
available sample. 
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3.2 | X-ray Diffraction Experiments 
 
3.2.1 | Choosing a Crystal 
The most apparent indicator of quality is shape; a good crystal should have well-
defined edges and not be curved or have ‘satellite’ crystals which cannot be removed 
from the surface. Crystals typically transmit polarised light, with three specific 
exceptions: tetragonal and hexagonal crystals if viewed along the c axis, and cubic 
crystals. However, other features of the crystal (such as the crystal shape) would 
indicate they were something other than amorphous if transmission did not occur. As 
the crystals are rotated under the polariser, the transmission should be even across the 
whole crystals and at some but not all crystal orientations. Non-crystalline material will 
not display this behaviour. Under cross-polarisation, crystals which transmit polarised 
light will be extinguished; this can be used to help identify if the examined crystal is 
singular as extinction should be sharp and complete.  The size of crystal necessary for 
diffraction depends largely upon the equipment being used. For example, the 
protonated peptoid precursor crystal used for analysis had dimensions 200 µm x 100 
µm x 100 µm, but structure determination was still possible.  
 
3.2.2 | Harvesting a Crystal 
Once a crystal (or in some cases, crystals) had been chosen, attempts would be made to 
remove them intact from the experimental solvent using a thin paper taper, and 
transfer them to a drop of inert oil on a glass slide with as much care as possible. The 
inert oil is more viscous than the experimental solvent, which can aid in manipulating 
the crystal, as well as securing the crystal once frozen in the mounting process. If 
clusters of crystals were grown which could be separated, or if smaller crystals were 
adhered to the main crystal which could potentially be removed, these crystals would 
also be harvested, and using the needle (or the taper, which is softer and so not as likely 
to cause destructive damage to the desired crystal) attempts would be made to 
separate the crystals. In the case of BDM41325, this led to a single crystal being 
removed from a large cluster. 
 Once crystals have been moved and provided they still hold up to the same 
standard once immersed in oil, the next step is to screen these crystals on the 
diffractometer.77 
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3.2.3 | Screening Crystals 
Crystal screening will reveal the practical diffraction quality of a crystal; crystals which 
appear to be good quality under a microscope can diffract poorly, and less attractive 
crystals can prove strong once tested.  
 The first step is to mount the crystal on the glass fibre on a pin. This is easiest 
when the pin is already secured in the goniometer head. Before attempting to pick up a 
crystal, the tip of the pin would be roughly centred on the diffractometer, making use of 
the attached camera. This would mean that once the crystal had been mounted on the 
goniometer head, it would be in a good starting position as soon as the head was 
secured. The aim is to use a minimal amount of oil when picking the crystal up on the 
tip of the fibre, enough to keep the crystal secure once cooled by the nitrogen-flow 
device, but not so much as to risk interfering with the diffraction. 
  
 
Figure 3.6 | The needle-shaped crystal of BDM41325 used for analysis,  
mounted in inert oil on a glass fibre on the goniometer head.  
Size: 300 µm x 20 µm x 20 µm. 
 
Once mounted, I would centre the crystal – this is not finding the centre of the crystal, 
but finding the centre of gravity of the crystal, so rotation will not cause dislodging or 
slipping, and the crystal will remain in the X-ray beam at all times. A camera is set up to 
aid centring, as can be seen in figure 3.7, above. Mounting needle-shaped crystals is 
something of a challenge, particularly as the needles are difficult to pick up on the fibre 
in the first place, but also because they are narrow and must be centred carefully. The 
crystal is rotated through phi while at a 60° omega angle, using small pins on the 
goniometer head to alter the angle of the fibre. Once the centre has been determined, it 
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is useful to move to a wider omega angle on the other side of the beam to ensure that 
centre of gravity remains steady and the crystal isn’t potentially going to be lost during 
the collection. 
 To test a crystal, single frames of a narrow width (typically 0.5° per frame) 
were taken, with phi at varying degrees (0°, 60°, 90°, 150°). Also, this is the ideal time to 
find the appropriate exposure time, should the crystal prove to diffract well. A good 
crystal will give intense reflections which do not exceed the detector limits, with well-
defined edges; smeared reflections will be difficult (if not impossible) to integrate 
reliably and doubled reflections are an indication of the crystal not being single.  
 If a crystal diffracts poorly, even with exposure times of up to a minute, then it 
is not worth wasting the time and energy to collect potentially unusable data; this 
happened frequently with my compounds, and in many cases there were other crystals 
to choose from until it was necessary to re-crystallise again. 
 If a crystal diffracts well, the first step is to determine the orientation matrix of 
the crystal. This is the process by which a limited number of frames are collected in 
order to determine a unit cell, or more accurately, determine the matrix function which 
relates the real-space unit cell to the reciprocal lattice distances. Enough data must be 
collected at different crystal orientations to gather as much information as possible 
from intense, well-formed reflections; most data collection software has a matrix 
strategy to collect the sufficient data.  
 
3.2.4 | Data Collection 
Attaining the unit cell dimensions has a three-fold role in the process of solving a 
structure. Firstly, a unit cell determination allows the crystallographer to make a 
decision about whether the compound is what is expected, using the 18 Å3 Rule. This 
‘rule’ is a fast way of determining if the volume of the cell matches the expected 
compound, based on each non-hydrogen atom having a volume of 18 Å3; it is a rough 
estimate, but can immediately flag any problems – salt rather than compound, for 
example. The second role of unit cell determination is to see whether the crystal 
diffracts well at a variety of phi and omega angles, and if the reflections remain as sharp 
and intense as the initial test. Finally, the unit cell determination leads to a 
determination of the crystal system, which informs how much data it is necessary to 
collect to achieve a complete data set. For example, more data would need to be 
collected on a monoclinic crystal than an orthorhombic crystal, which has a greater 
symmetry. If there is any doubt (such as a β angle very close to 90°, which could 
indicate orthorhombic character or simply a monoclinic cell with an incidentally ~90° 
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angle) then collecting with an assumption of a lower symmetry is safest, avoiding 
incomplete and unsolvable data. 
 Data for all compounds were collected on a Bruker MicroStar diffractometer 
equipped with a copper rotating anode X-ray source, Helios mirror monochromator  
system and a Platinum 135 CCD area detector. A combination of omega and phi scans 
were used at varying 2  angles. The 2  ranges for each data collection can be found in 
the relevant crystallographic data tables in the Appendix. The diffractometer is 
connected to a computer with software for designing, controlling, saving and 
processing the data collection.78 
 
 
 
Data collection strategy software was used for designing the diffraction experiment. 
The strategy uses the unit cell determination to suggest the scans necessary to achieve 
a high completeness and reasonable redundancy, with an expected duration for the 
collection based upon the exposure times for each frame. With higher symmetry in the 
crystal, there is a small portion of unique data necessary to cover the entire crystal 
structure, with a greater number of equivalent reflections. Again, if there is any doubt, a 
lower symmetry class should be chosen so that all of the unique data is collected 
(completeness) and then as much data as time allows; repeated collection of equivalent 
reflections is termed ‘redundancy’. The data collection strategy is particularly useful 
after a stock set of scans has been entered or even performed, as it will ‘fill in the 
blanks’ and select scans from a virtual bank of possible scans to increase completeness 
and redundancy. If time is an important factor in the data collection, a target can be set 
to optimise the scans chosen; data collection is a trade-off between completeness and 
time.  
 The anionic peptoid precursor, BDM41420 and BDM41907 were collected 
using a manually chosen data collection strategy, which was sufficient for completeness 
of the data. For the protonated peptoid precursor, BDM31343 and BDM41325, the data 
collection strategy was utilised to design an optimum data collection within a set time-
Figure 3.7 | The collimator controls the width of the 
beam, and is perfectly aligned with respect to the 
beam from the source and the goniometer. The 2  
angle is determined by the position of the detector; 
the ϕ angle is the rotation of the pin around 360°; 
the ω angle is the rotation of the goniometer head. 
The nitrogen flow device for cooling crystals 
throughout collection is not shown for the clarity of 
the image. 
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frame. Further details regarding the diffraction experiments on the six crystals can be 
found in the Appendix. 
 
3.2.5 | Data Processing 
Once collected, data were merged, integrated and scaled using SAINT;78 absorption 
corrections were performed using SADABS, conducted automatically by SAINT. The Rint 
statistic is a measure of the internal consistency of the unprocessed data. The 
programme XPREP78 is used to examine the systematic absences in the reflection data 
to determine the space group of the crystal. An Rsym value provided for the suggested 
space groups can inform the decision should there be any doubt. Finally, XPREP writes 
the files required for structure solution by SHELXS-97.69 
 All structures were solved using direct methods by SHELXS-97, and refined by 
least squares methods against F2 using SHELXL-97 through the Olex2 interface.79 For 
each structure, all non-hydrogen atoms were refined with anisotropic displacement 
parameters and all hydrogen atoms were unambiguously identified and refined 
isotropically on calculated positions using a riding model. Further crystallographic 
solution and refinement details on each of the six crystal structures can be found in the 
Appendix. 
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3.3 | AutoDock Vina 
 
3.3.1 | Theory: Molecular Docking 
AutoDock Vina (often referred to as simply ‘Vina’) is a molecular docking software 
which predicts binding affinities and the bound conformations of ligands with receptor 
molecules - typically small organic molecules to proteins.10 
 Molecular docking is a computational approach to protein-ligand binding when 
experimental data has not yet been acquired. In all computational methods, there is an 
inevitable trade-off between exhaustive accuracy and speed; the algorithm utilised by 
Vina is an iterative process from a random starting seed position of the ligand, which 
seeks to maximise the accuracy of the determined conformation and binding affinity 
with a manageable computational time. 
 Docking in this form is a statistical method utilising biomolecular force fields.80 
The binding affinity of ligand to protein is determined by structural and energetic 
compatibility; the biomolecular force fields are comprised of a large number of energy 
terms for covalent and non-covalent interactions. The force field calculations assume a 
vacuum, but use empirical data to give appropriate, consistent values for the force field 
parameters. For example, structural data (such as crystal structures) give molecular 
geometry and bond lengths and torsions to inform movement; spectroscopic data give 
molecular vibrations and force constants, whereas thermodynamic data give the 
partition co-efficient. Experimental data from small molecules calibrate the docking 
calculations to ensure high-probability results with reliable accuracy.81 
   
3.3.2 | Using Vina 
Certain assumptions are made in order to decrease the time and detail of the 
computations necessary to determine the result. First, Vina assumes the protonation of 
both the ligand and protein remain the same between the bound and unbound states. 
Second, Vina assumes the receptor remains rigid, with constant and unchanging bond 
lengths, bond angles and torsion angles; with the preparation of particular input files, 
however, Vina is capable of taking some flexible residues into account. Finally, Vina 
requires the user to specify the rotatable bonds of the ligand. 
 Vina has various defaults built in to the computational process, which can be 
specified. For example, Vina will start at a random seed position if one is not specified; 
unless included in the instruction configuration file, a maximum of nine binding modes 
will be reported with the difference between the first (and best) and the ninth (with the 
lowest binding affinity) being no more than 3 kcal/mol; the exhaustiveness of the 
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search is given an arbitrary value on a linear scale with time, with the default value of 
‘8’ – increasing this exhaustiveness will increase the computational time but will 
increase the accuracy of the results.  
 The result of the Vina run is a number of binding modes with 3D co-ordinates, 
given with the binding affinity of the ligand and protein for each mode. In addition, the 
RMSD of each mode successive binding mode is compared to the best result and 
reported. Two RMSD values are given, one is the ‘lower bound’ or ‘lb’ and the other is 
the ‘upper bound’ or ‘ub’. The upper bound RMSD is defined in the Vina manual as the 
statistical match of each atom in one binding mode with itself in the top binding mode, 
ignoring any symmetry. The lower bound RMSD utilises rmsd’ to give an RMSD where 
each atom in one binding mode is matched to the closest atom of the same element 
type. Below is an example of the statistical read-out from Vina (figure 3.8).  
 
Figure 3.8 | The log file of a Vina run, detailing the random seed position used and the eight binding modes 
determined with their relative RMSD values and binding affinities. Details of this run are described in 
section 3.3.3, where a ligand was removed from a co-crystal structure to test Vina. 
 
The two RMSD values inform differently, as a rigid symmetrical ligand such as a 
benzene ring could be rotated 180°; the RMSD/ub would give a significantly higher 
result than the RMSD/lb, where the upper bound takes into account the movement of 
specific atoms, whereas the lower bound would only take into account the nearest atom 
of the same type. 
 Finally, Vina generates the co-ordinates of the calculated binding mode in 
relation to the protein, and saves these in the same format as the input file to be 
viewed. Vina uses a unique type of input file. The standard PDB format does not carry 
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information which Vina requires (hydrogen atoms, charges and atom assignments), and 
so and extended format, PDBQT, is used instead. These files can be prepared in the 
AutoDock visualiser AutoDock Tools (ADT) from the PDB files. This interface is also used 
to determine the search space or ‘grid box’. 
 
3.3.3 | Testing Vina 
In order to understand how best to utilise Vina for docking the inhibitor crystal 
structures to EthR as well as determine just how accurate Vina was, the following test 
model was used: the published co-crystal structure (PDB: 31GM) of EthR with 
BDM31381.99 Using ADT, the ligand was separated from the protein structure into 
separate PDB files. Following this, the ligand file was prepared by assigning the 
rotatable bonds of the molecule and subsequently written out in PDBQT format; the 
protein file was prepared by deleting the water molecules (which Vina cannot take into 
account), adding polar hydrogens to the structure, assigning the charges and the atom 
names and finally writing out the unbound EthR structure for docking. The intention 
was to use different search spaces volumes to assess two things: (a) how closely Vina 
could determine the experimental binding mode (by comparing the resulting modes 
with the experimental 3G1M structure) and (b) how long a run upon a search space can 
be expected to take. 
 The result of this exploratory test showed that Vina was most accurate with an 
increasingly exhaustive search of the entire protein structure (with a box volume of 
126,720 Å3). The default value of exhaustiveness is 8, which was steadily increased to 
40; with no other alterations to the programme configuration, this took only twenty 
minutes. The runs were conducted on a personal laptop running Windows 7, equipped 
with 4GB RAM and a 2.2GHz dual-core processor. The log file of the initial test can be 
seen as figure 3.8, above. Therefore, it was decided that Vina would perform exhaustive 
runs on the whole protein search space with each ligand - and this model form of 3G1M 
- with an empty ligand-binding site in a ligand-binding conformation. 
  
3.3.4 | Method: Vina applied to EthR inhibitors 
Based upon observations made by Willand et al.,55 where the movement of two 
phenylalanine residues in the EthR structure were seen to be rotatable and as such, 
could open up an auxillary binding pocket for longer ligands, Vina was instructed to 
compute binding with these two residues as flexible in the ligand-binding channel. This 
required preparation of three input files in ADT: the ligand file (one for each of the four 
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inhibitor crystal structures), the torsions of the flexible Phe114 and Phe184, and the 
rigid protein without these two residues.  
 Normally, Vina considers the protein as rigid and the ligand as flexible in 
user-specified rotatable bonds. However, by including flexible residues, the user is able 
to select rotatable bonds in the side chains (Phe114 and Phe184 in this case) while the 
rest of the protein remains rigid. However, there is a computational cost and an 
increase in time required. 3G1M was used as the protein model because the co-crystal 
structure contained a ligand of a similar size with the same base chemical structure as 
the ligand crystal structures determined. The following configuration file was used for 
each run: 
 
 
  
  
 
 
Figure 3.9 | Configuration file for AutoDock Vina runs. 
 
The receptor, flex and ligand fields specify the source files (figure 3.9, above), with the 
out field giving a file name for the co-ordinates of the binding modes and the log field 
giving a file name for a log file to be written; the center and size fields define the search 
space; the exhaustiveness field, as described above, determines how long and detailed 
the iterative process should be. Each of the four docking runs (one for each compound) 
took roughly 45 minutes. The results of these docking runs are summarised for each 
compound in chapter four, with more detailed discussion in chapter six.  
 
receptor = 3g1mrig.pdbqt 
flex = 3g1mflex.pdbqt 
ligand = XXX.pdbqt 
out = outputXXXflex.pdbqt 
log = logXXXflex.txt 
exhaustiveness = 40 
num_modes = 4 
 
 
 
center_x = 26 
center_y = 74 
center_z = 7 
size_x = 68 
size_y = 48 
size_z = 36 
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CHAPTER 4 
2RESULTS & DISCUSSION: PEPTOIDS 
 
4.1 | Anionic Peptoid Precursor 
The anionic precursor is an intermediate product of the target peptoid formation.82 The 
crystal structure of this anionic peptoid precursor revealed it be a sodium salt (figure 
4.1). 
 
Figure 4.1 | Asymmetric unit of the anionic peptoid precursor. All bond lengths and angles determined 
were as expected. 
                                                                
For both the anionic and protonated precursor form, the full crystallographic details (including bond lengths 
and angles, and figures showing the 50% probability anisotropic ellipsoids of constituent atoms) can be found 
in the appendix as sections A-I and A-II. All images were created in Olex2.79 
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4.1.1 | Structural Analysis 
The central C1 atom is trigonal, with the C1-N3 bond displaying double bond character 
- evidenced by a bond length of 1.338(13) Å. The sodium ion co-ordinates two oxygen 
atoms in the asymmetric unit, however in the wider crystal structure, the sodium ion is 
trigonal bipyramidal (figure 4.2), with the five co-ordinate sodium ion holding two 
anions and three bridging water molecules in place.  
 
However, the angle formed by the axial atoms O3-Na-N2 is 177.4°, which is distorted 
from the ideal 180° (figure 4.3). Similarly, the equatorial positions are not at 90° to 
these axial positions. Specifically, the angle O3-Na-O3’ is reduced to 73.4°, but the angle 
formed by O3-Na-O4 is widened to 118.9°, due to sodium from another molecule co-
coordinating with the shared oxygen atoms. From this we can surmise that hydrogen 
bond interactions as well as the sodium co-ordination determine the crystal packing 
structure, as can be seen in figures 4.2 and 4.4. 
 
 
Figure 4.3 | The co-ordination around the sodium ion (a) is not perfectly trigonal bipyramidal – angles 
shown in b are the expected trigonal bipyramidal arrangement about central atom/ion X. 
 
There is an observed delocalization of electrons across the perfluoropyridyl rings, 
evidenced by the equivalency in the carbon-carbon bond lengths of the heterocycles.  
Figure 4.2 | Cell-centered image of the 
anionic peptoid precursor, viewed 
along the c axis. A clearer image of the 
crystal structure itself is given in 
figure 4.4, overleaf. 
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 The NO2 group is involved in hydrogen bonding, and there is evidence to 
support the two nitrogen-oxygen bonds being equivalent. A typical nitrogen-oxygen 
single bond has a distance of approximately 1.40 Å, and a double bond is typically 
around 1.21 Å;  the N3-O1 and N3-O2 bonds are of almost identical length - 1.282(11) Å 
and 1.288(11) Å respectively, forming an O1-N3-O2 angle of 120.7°. This potentially 
gives a more localised charge to the NO2 group, increasing the potential for electrostatic 
bonding. 
 
4.1.2 | Crystal Packing Interactions 
Expanded from the asymmetric unit, the crystal structure of the anionic peptoid 
precursor is demonstrated below. The structure itself is held together by the co-
ordination around sodium ions and hydrogen bonds formed by oxygen atoms (figure 
4.4, overleaf). 
 There are two key hydrogen bonds repeated in the packing structure, shown as 
dotted lines in figure 4.5 below; the second Na-N2 ionic bond is shown for clarity. The 
O1-H3a (1.968 Å) and N1-H4b (2.227 Å) bonds stabilize the co-ordination around the 
sodium ion and maintain the positions of the perfluorinated pyridyl rings. 
 Though potential stacking interactions were anticipated between the 
perfluoropyridyl groups,83 the conformation of the precursor does not support it. The 
planes of the two rings are at a 95.2° angle with respect to each other, and the co-
ordination of the sodium ion in the structure precludes π-π interactions. However, this 
does not prevent the potential for this kind of non-polar interaction in a covalently 
linked sequence of peptoid or peptoid-based molecules. 
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Figure 4.4 | Crystal structure of the anionic peptoid precursor. 
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4.2 | Protonated Peptoid Precursor 
The precursor was prepared82 with the intention of isolating the reduced product. The 
asymmetric unit of the crystal structure was determined to be the protonated form of 
the peptoid precursor. 
 
Figure 4.5| Asymmetric unit of the protonated peptoid precursor 
 
 
 
4.2.1 | Structural Analysis 
Unlike the anionic precursor form, the protonated peptoid precursor shows a typical 
tetrahedral formation about the central C1 atom due to the addition of hydrogen. The 
C1-N3 bond shows a carbon-nitrogen single bond distance of 1.487(4) Å, longer than 
the corresponding bond length in the anionic form. The new arrangement around C1 is 
less restrained by this single bond and as a result, the planar perfluoropyridyl rings are 
oriented at an angle of 100.3°, greater than in the anionic form (95.2°). The same 
Figure 4.6 | Cell-centered image of 
the protonated peptoid precursor 
molecule. The crystallographic 
inversion centre is evident in the 
centre of the cell. 
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delocalization of electrons over the heterocyclic rings, as seen in the anionic form, can 
be observed in here. 
 The NO2 group, in contrast to the anionic form, does not show equivalent 
nitrogen-oxygen bonds. Though the angle formed is similar (O1-N3-O2 angle of 123.9°) 
the two bonds are distinctly different. The N3-O1 bond, with a distance of 1.200(4) Å, 
and N3-O2 bond, which is 1.246(4) Å, are equivalent; the bonds differ only slightly from 
the expected 1.21 Å length for the N-O bonds of an NO2 group. 
  
4.2.2 | Crystal Packing Interactions 
As with the anionic form, there are no π-π interactions of the ring systems, and instead 
of packing through sodium co-ordination, hydrogen bonds are formed between 
molecules through the hydrogen atom (figure 4.7). 
 
Figure 4.7 | Hydrogen bonding stabilizes crystal packing; H1⋅⋅⋅N1’ has a distance of 2.467 Å. 
 
Also present is evidence of C-F⋅⋅⋅π interactions. The F13 atom is 3.259 Å from the plane 
of the C21 ring of the adjacent molecule (figure 4.7). Due to the delocalisation of 
negative charge across the perfluorinated ring, the centre of the ring is relatively 
electropositive; F13 is electronegative. Interactions of this nature have been shown to 
be widespread amongst fluoro-organic crystal structures.84 Therefore, the only 
interactions maintaining this packing structure are the N1⋅⋅⋅H1 hydrogen bonds and 
the F13⋅⋅⋅π electrostatic attraction. 
 This implies that the crystal packing is not tightly held, particularly in 
comparison to the anionic precursor form, giving some explanation as to the formation 
of two different crystal habits (section 3.1.7). Without determining the structure of the 
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alternative, needle-shaped crystal habit, it is impossible to say whether hydrogen 
bonding was occurring between different atoms, however it could be suggested that the 
alternative habit arises from hydrogen bonds between H1 and N2, O1 or O2. It is 
unfortunate that these needle-shaped crystals were too small to analyse, for the sake of 
a complete picture of the potential packing arrangements. 
 The crystal packing interactions of the monomeric precursor forms gives an 
insight into the interactions which could form in a multimer, dictating secondary 
structures.   
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4.3 | Implications for Use as Peptoids 
To transition into potential use as peptoids, the precursor molecule (specifically the 
protonated form, as the anion would not be appropriate for a peptoid-based peptide 
mimic as suggested in chapter two) would have to undergo reduction (figure 4.8). 
 
Figure 4.8 | Scheme for synthetic preparation of a peptoid from a precursor.82 
 
Although the NO2 group is present in the precursor form, it would be reduced to an NH2 
group in the peptoid; this would be condensed to then create a linkable peptoid for 
oligomerization (figure 4.9). Therefore, the hydrogen bonding potential of this group, 
found in the anionic form, is not available here. 
 
Figure 4.9 | Given the schematic for a peptoid, left, the potential peptoid formed from the protonated 
precursor would have a chemical structure such as that on the right. 
 
As these two perfluorinated rings are bulky, the backbone and secondary structure of 
any oligomeric peptoid would be highly distorted from a typical α-helix. However, the 
nitrogen atoms of the perfluorinated pyridyl rings are still available for hydrogen 
bonding, as would be the hydrogen of the N-linkage.  
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CHAPTER 5 
3RESULTS AND DISCUSSION: ETHR INHIBITORS 
 
5.1 | BDM31343 
The crystal structure of the first inhibitor compound was determined, with the contents 
of the asymmetric unit – one molecule of the inhibitor – shown as figure 5.1. 
 
Figure 5.1 | Asymmetric unit contents of BDM31343. All bond lengths and angles were as expected. 
 
Figure 5.2 | Chemical structure of BDM31343. 
 
It is of note that the oxadiazole ring takes an orientation distinct from the chemical 
structure given in Willand et al., 2009, which can be seen as figure 5.2, above. This 
results in an S1⋅⋅⋅N2 distance of 3.086 Å, a potential source of non-bonding interactions 
between the ligand and the protein. A similar intramolecular interaction was suggested 
by Flipo et al., 2011 based on the co-crystal structure of EthR and BDM31381, in which 
a sulphur in the second thiophene ring was within 3.5 Å of the carboxyl oxygen atom, 
however BDM31343 does not share that structural group. Interestingly, the published 
                                                                
Full crystallographic details for all four inhibitor structures (including bond lengths and angles, and figures 
showing the 50% probability anisotropic ellipsoids of constituent atoms) can be found in the appendix as 
sections A-III to A-VI. All images were created in Olex2.79 
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structure of BDM31381 with EthR (PDB: 3G1M) shows the inhibitor as drawn in the 
chemical structure, with S1 and N2 in a trans conformation. The 3G1M crystal structure 
has a resolution of 1.7 Å, which should be sufficient to accurately identify the atom 
positions of the bound ligand BDM31343. The structure shows electron density around 
the thiophene ring which would support the orientation observed in the BDM31343 
crystal structure rather than the one presented in the refined co-crystal structure, 
implying an incorrectly modeled ligand in the published EthR-BDM31343 complex. 
 The thiophene ring of BDM31341 and the oxadiazole ring are planar (RMSDs of 
each ring are 0.003 Å and 0.001 Å respectively). The angle between these ring planes is 
5.6°, meaning the compound crystallizes with these two rings nearly, but not quite, 
planar to each other. This conformation would be supported by an intramolecular 
interaction between S1 and N2. Though the oxadiazole ring is capable of both polar and 
possible stacking intermolecular interactions to stabilize the crystal packing, only the 
O1 atom makes any connections within a suitable distance to this effect.  
 
Figure 5.3 | Crystal packing of BDM31343. Interactions between atoms are shown in red. 
 
Atom O1 of the crystal structure is within the expected 4 Å van Der Waals distance74 of 
two hydrogen atoms, one positioned in a molecule above (taking the furthest left 
molecule as the example, this would be H13A) and the other in a molecule below (H3A). 
The orientation this enforces upon the rest of the molecule precludes any π-π stacking 
interactions involving either the oxadiazole, piperidyl or thiazole rings. However, O1 
also forms an intramolecular interaction with H1A (at a distance of 2.379 Å) which 
would be responsible for ensuring the nitrile ‘tail’ of the molecule is held at a specific 
angle.  
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 The interactions present in this crystal structure would suggest that the ability 
of BDM31343 to form similar interactions with the ligand binding channel of EthR 
would be largely dependent of the position and orientation of O1. 
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5.2 | BDM41420 
BDM41420 shares a similar core structure to BDM31343, with a piperidyl ring and 
carboxyl group. However, in place of an oxadiazole linker, there is an oxazole – this 
structure has no N3 atom. Furthermore, the sulphur is no longer present and instead a 
phenyl ring takes the place of the thienyl found in BDM31343; in the place of the nitrile 
is a trifluorocarbon group, which infers more possibility for intermolecular bonding. 
 BDM41420 crystallised with two distinct molecules in the asymmetric unit, 
unlike the previous crystal structures where the Z’ – the parameter which is used to 
define the number of molecules in the asymmetric unit – is equal to 1. These two 
molecules are overlaid in figure 5.4, below. 
 
Figure 5.4 | Least squares superimposition of the two molecules of BDM41420 in the asymmetric unit 
(inset). There is a non-crystallographic centre of inversion in the asymmetric unit. 
 
The two molecules BDM41420 match, with an inversion of one molecule, with an RMSD 
of 0.217 Å. This shows that the two molecules are chemically identical, yet structurally 
distinct enough to be considered different. What has been unintentionally captured is 
an indication of a flexibility of the molecule, even though crystallography is typically 
technique which produces static, averaged snapshots of a crystal structure.  
 The overlay reveals movement primarily in the phenyl ring (which is planar, 
within 0.004 Å) and around the tetrahedral CF3 group. The C3 atom has a mildly 
distorted tetrahedral geometry in both molecules as it is part of the oxazole ring, so 
that O2-C3-C2 and O2-C3-C4 angles are 107.7(9)° and 107.2(9)° respectively, and the 
C2-C3-C4 angle is 110.8(9)°; this also leads to the oxazole no longer being planar, as 
seen in BDM31343.   
 The intramolecular interaction of O1 with H1A is seen in both molecule 1 (at a 
distance of 2.354 Å) and molecule 2 (O3⋅⋅⋅H22A with a distance of 2.338 Å). The 
 
 
 
 
65 
interaction occurs on the alternate side of the piperidyl ring in molecule 2, indicating 
the piperidyl-oxazole ring has inverted; this is the cause of the difference between the 
two molecules in the packing structure.  
 
Figure 5.5 | Example of crystal packing in BDM41420. Note that while the orientation of the molecules in 
the figure suggests π-π stacking, this is not the case. 
 
The crystal packing structure is also supported by hydrogen bonds made by N2, O1 and 
F3 with hydrogens (H23A, H15B and H16B respectively) in molecule 2 – with the 
equivalent atoms in alternate molecules; fluorine hydrogen bonds are a strong 
determinant of crystal packing in fluorine-substituted rings.85 However, the structure 
shows no evidence of π-π stacking, just as observed in BDM31343. Overall, this implies 
more opportunity for protein-ligand binding, even with the reduction of flexibility 
caused by specific arrangement around the C3 atom. 
 The presence of two molecules in the asymmetric unit (Z’ = 1) is an important 
feature of the crystal packing. An Z’ >1 can be a result of various factors including 
chirality or an increased ability to make hydrogen bonds, but the underlying laws 
governing crystal packing are not well understood. A study of the Cambridge 
Crystallographic Database quotes the frequency of a Z’ > 1 as being 8.8% across the CSD 
as a whole, and 11.5% for organic structures.86 Of these structures, the most common 
space group is P21/c, which accounts for almost 27% of the CSD structures with Z’ =2;87 
the separate molecules are typically observed to avoid the crystallographic glide plane 
and to pack in such a way as to minimize the packing surface area, usually with a non-
crystallographic inversion centre.88 This inversion centre can be seen in the figure 5.4.
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5.3 | BDM41907 
The structure of BDM41907 revealed it to have the same core structure as BDM31343, 
with some of the modifications seen in BDM41420. This structure possesses an 
oxadiazole linker, a trifluorocarbon group and the essential piperidyl ring with a 
carboxyl group attached at N1. However, unlike the two previous molecules, 
BDM41907 possesses a methyl-sulphoxide group linked at C11. 
 
Figure 5.6 | Asymmetric unit (one molecule) of BDM41907 
 
The oxadiazole ring is planar (RMSD of 0.003 Å), as is the phenyl ring (RMSD of 0.006 
Å). The two rings are not perfectly planar with respect to each other, being at an angle 
of 7.4° - however this reflects a similar arrangement observed in BDM31343, 
suggesting that the lowest energy conformation in the crystal packing structure 
benefits from the planarity of these rings, despite them forming no π-π stacking 
interactions. 
 BDM41907 contains a longer chain between the carboxyl group and the 
triflurocarbon group than seen in BDM41420 by one CH2. This longer molecule can 
potentially occupy a larger portion of the ligand-binding channel, forming more 
intermolecular interactions and prospective tighter binding effect; molecular docking 
analysis will reveal if this is the case (section 5.5). 
 Though sulphur is present in this structure, it is not in a position capable of 
forming intramolecular interactions with any nitrogen or oxygen present in the 
molecule. Figure 5.7, overleaf, indicates three of the main hydrogen bonds which hold 
the packing structure, made by O3, O4 and F3. The methyl-sulphoxide groups of two 
adjacent molecules (O3⋅⋅⋅H19A’ and O3’⋅⋅⋅H19A at 2.435 Å  interact to bring the 
 tructure  into alignment; interaction  formed by O4 with H15B’  at a di tance of 2.404 
Å  and  3’ with H10A ensure that the rest of the molecule is held in place in the crystal 
structure. The intramolecular interaction between O1 and H1A at a distance of 2.323 Å 
indicates that some intramolecular stabilization of the long, flexible ligand is occurring; 
this was observed in BDM31343 and BDM41420. 
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5.4 | BDM41325  
The crystal structure of BDM41325 showed that although it possesses the same core 
piperidyl-carboxyl link seen in the other three compounds, BDM41325 is structurally 
distinct. BDM41325 possesses a methoxyl-benzothiazole group connected to the 
oxadiazole linker; this is the longest ligand of the four crystallised. 
 
Figure 5.8 | The crystal structure of one molecule of BDM41325. 
 
The structure, from the planar oxadiazole ring (RMSD of 0.003 Å) to the trifluorocarbon 
group, is similar to previous ligands. The benzothiazole group is practically planar (the 
phenyl and thiazole rings have a relative angle of 0.2°), while the angle between the 
thiazole and the oxadiazole is slightly less planar, at 4.9°; the former is more restrained 
than the latter due to the shared C9-C14 bond. The same potential intramolecular 
interaction between S1 and N2 is present here as in BDM31343, at a distance of      
3.063 Å.  
 As with the previous ligands, the interaction between the carboxyl oxygen and a 
hydrogen i  pre ent,  een a  O1⋅⋅⋅H5B  2.309 Å , and there i  no evidence of π-stacking 
in the crystal structure. Although BDM41325 the methoxyl group, this atom is not 
involved in the formation of intermolecular interactions for crystal packing (figure 5.9, 
overleaf). In fact, despite more opportunities for polar intermolecular bond formation 
(in S1, N4 and O3), there are only two interactions dictating the packing configuration: 
F3⋅⋅⋅H12A’  2.604 Å  and O1⋅⋅⋅H17A’’  2.335 Å . Thi  i  unexpected, and could be a 
feature of the crystal packing conformation, rather than an inability of these atoms to 
form such putative interactions. 
 BDM41325 is the longest of the inhibitors crystallised, and as such is the most 
likely to cause the opening of the auxiliary pocket in the ligand-binding channel of EthR, 
if any of the ligands were capable of doing so. 
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5.5 | Molecular Docking of EthR Inhibitors 
Molecular docking was conducted on each ligand with EthR in a ligand-bound 
conformation with two flexible phenylalanine residues, using AutoDock Vina.10 Details 
of how this was achieved can be found in chapter three, section 3.3. 
 
5.5.1 | Molecular Docking of BDM31343 
The results of the molecular docking algorithm are summarized in table 5.1, below, 
ranked by calculated binding affinity.  
 
Mode Affinity (kcal/mol) Distance RMSD –l.b. Distance RMSD –u.b. 
1 -9.1 0.000 0.000 
2 -8.1 1.725 2.229 
3 -8.0 2.761 4.953 
4 -7.9 1.812 2.760 
Table 5.1 The four best binding modes as determined by AutoDock Vina for BDM31343. Definitions of 
lower and upper-bound RMSD can be found in section 3.3.2 in chapter three. 
 
The binding modes suggested are very different, with binding mode 3 showing the 
highest RMSD values and so being the most distinct from mode 1; this is clearly visible 
in the graphical representation in figure 5.10. 
 
 
 
Figure 5.10 | Comparison of the four binding modes as determined by AutoDock Vina. Numbers 1-4 in 
image refer to modes in table 5.1; flexible Phe residues are shown in blue. 
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Figure 5.11, right, shows a superimposition of binding mode 1 
with the original ligand position in the protein structure. The 
flexible phenylalanine residues computed, Phe114 and Phe184, 
adopt very similar positions in both the docked and original 
crystal structure. The docked ligand occupies a near-identical 
position as the original ligand, however the orientation has been 
reversed so the carboxyl tail is towards the aperture of the 
pocket rather than the top of the channel.  
 Binding mode 1 is shown below as figure 5.12, with the 
orientation altered for clarity. The key residues likely to be 
involved in this binding event are two asparagine side-chains and 
a phenyl alanine. The ligand is oriented such that the thienyl 
points to the top of the channel and the nitrile to the aperture. 
There are few side-chains projecting into the channel at the 
bottom of the channel; despite the potential for polar contacts 
between the ligand and protein from the carboxyl, these do not 
appear to occur. Instead, the thienyl sulphur atom is oriented to 
interact with the carboxyl of the Asn176 back-bone, while the carboxyl of the Asn176 
side-chain is able to interact with N3 of the oxadiazole ring. The oxadiazole ring also 
forms a potential hydrogen bond with the NH2 group of the side-chain. There is also 
some suggestion of π-stacking between the oxadiazole ring and Phe110.  
 
 
Figure 5.12 | Image of docked BDM31343, with key interacting residues and relative distances displayed.
Figure 5.11 | Overlay of 
binding mode one of 
BDM31343 with the 
original ligand 
(BDM31381 and Phe 
residues shown in black 
lines) of 3G1M (PDB). 
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5.5.2 | Molecular Docking of BDM41420 
Though there were two structurally distinct molecules in the crystal structure of 
BDM41420, only one set of co-ordinates was needed for the docking run as the 
differences arise from the changes in torsion angles – which are variable in docking. 
 
Mode Affinity (kcal/mol) Distance RMSD – l.b. Distance. RMSD – u.b. 
1 -9.4 0.000 0.000 
2 -9.0 5.396 8.533 
3 -8.8 4.073 7.372 
4 -8.4 3.640 7.441 
Table 5.2 The four best binding modes as determined by AutoDock Vina for BDM41420. 
 
Four binding modes for BDM41420 were calculated with affinities 
within 1 kcal mol-1. The RMSD values for each binding mode show 
modes 2, 3 and 4 are statistically, significantly different from mode 
1 (table 5.2). The molecular docking results for BDM41420 show 
very little movement in the phenylalanine residues from the 
original protein structure, as can be seen in figure 5.13, right; as 
the shortest ligand, this would indicate there is more opportunity 
to bind in the channel without expending energy to open up the 
auxiliary binding pocket.  
 The differences in binding position shown by the RMSDs in 
table 5.2 are more clearly represented in figure 5.14, below.  
 
 
Figure 5.14 | Comparison of the four binding modes as determined by AutoDock Vina. Numbers 1-4 in 
image refer to modes in table 5.2, above. 
Figure 5.13 | 
Overlay of the 
original ligand and 
Phe residues with 
binding mode 1. 
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As figure 5.14 (right) also shows, BDM41420 occupies a position in the best binding 
mode which corresponds to the position of the original ligand. Despite the overall 
movement of the ligand throughout the four binding modes, the mid-point of the pocket 
is always occupied, whether by the phenyl ring in mode 2, the oxazole ring in mode 3 or 
the piperidyl ring in mode 4; this suggests the conformational change in the overall 
protein structure is reliant upon occupation of this area by a ligand. 
 The highest ranked binding mode of BDM41420 according to Vina, shown 
below in figure 5.15, forms both polar and non-polar intermolecular interactions with 
similar residues to BDM31343 (figure 5.12), but the orientation of the ligand results in 
these contacts occurring with different ligand atoms. The ligand itself has the phenyl-
oxazole end of the ligand at the bottom of the channel, towards the wide, more open 
area; the trifluorocarbon tail is extended toward the top of the pocket. 
 The carboxyl oxygen atom of the ligand is in a position to form a hydrogen bond 
with the NH2 of the asparagine side chain (Asn179) at a distance of 3.04 Å. The carboxyl 
of Asn176 is 3.59 Å from N1 in the piperidyl ring, which can be a source of 
intermolecular interaction. However, the oxazole ring has no discernable side-chain 
interactions, nor is it able to rotate freely to do so as the oxazole shares C3 with the 
piperidyl ring. Potential hydrophobic van der Waals interactions can be made between 
Phe110 and C15 of the carbon tail.  
Figure 5.15 | Image of the top docking result for BDM41420, with key interacting residues labelled with 
relative distances. The orientation has been altered for a clearer image. 
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Figure 5.16 | Overlay 
of the original ligand 
and mode 1. 
5.5.3 | Molecular Docking of BDM41907 
The four binding modes suggested share very different orientations within the ligand-
binding channel, with the computed flexible Phe114 and Phe184 showing very little 
movement (figure 5.16). 
 
Mode Affinity (kcal/mol) Distance RMSD – l.b. Distance RMSD – u.b. 
1 -10.6 0.000 0.000 
2 -10.6 0.647 1.575 
3 -9.8 2.592 3.083 
4 -9.2 2.001 2.907 
Table 5.3 The four best binding modes as determined by AutoDock Vina for BDM41907. 
 
The best binding mode (though all four suggested modes share this 
orientation) shows the ligand with the methyl-sulphoxide group 
pointed towards the top of the ligand-binding channel. The position of 
the mode 1 in the ligand-binding channel corresponds directly to the 
position of the original ligand (figure 5.16). 
 Modes 1 and 2 are calculated to have the same binding affinity 
(-10 kcal mol-1); the sulphoxide groups are in near-identical positions, 
but the carbon chain is twisted further up in mode 2. Mode 3 shows 
movement in both the carbon tail and the methyl group, whereas 
mode 4 shows the ligand slightly higher in the pocket, with 
alternative torsions to the planar phenyl and oxadiazole rings, as well 
as the piperidyl ring.  
 
Figure 5.17 | Comparison of the four binding modes as determined by AutoDock Vina. Numbers 1-4 in 
image refer to modes in table 5.3, above. 
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In the ligand-binding channel, BDM41907 has key interactions with Asn176 and 
Asn179, which were indicated to have a similar role in the previous two ligands (figure 
5.18); here they both potentially form polar interactions with O3 – Asn179 at a distance 
of 3.15 Å and Asn176 at the slightly shorter distance of 2.98 Å. Phe110, which was 
shown to have potential interaction with the previous ligands is not indicated to do so 
here, instead, Tyr148 is implicated. The carboxyl oxygen atom O1 in BDM41907 is in a 
position to form a hydrogen bond with the OH functional group of the tyrosine residue, 
an interaction so far unique to this ligand. Despite the size and availability of the 
trifluorocarbon group, no residues around the bottom of the pocket are within 4-5Å for 
interaction.  
 
 
Figure 5.18 | Close-up of the best binding mode in the ligand binding site with key residue interactions 
highlighted. The orientation has been altered for a clearer view of the residues and distances. 
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5.5.4 | Molecular Docking of BDM41325 
Binding mode 1 is the most “energetically favourable” as it has been ranked the highest 
by Vina with the greatest binding affinity (table 5.4).  
 
Mode Affinity (kcal/mol) Distance RMSD – l.b. Distance RMSD – u.b. 
1 -10.4 0.000 0.000 
2 -10.2 1.582 2.721 
3 -10.1 5.843 10.619 
4 -10.0 1.290 1.846 
Table 5.4 The four best binding modes as determined by AutoDock Vina for BDM41325. 
 
The RMSDs of modes 2, 3 and 4 show they adopt distinctly 
different positions to mode 1, but it is mode 3 which 
differs the most. Figures 5.19 (right) and 5.20 (below) 
show mode 3 is the only mode which involves the 
movement of Phe184 to allow the ligand to occupy a 
position higher in the ligand binding channel. Figure 5.19 
shows the mode 1 ligand bound at a similar position as 
the original ligand, with little movement in the 
phenylalanine residues chosen as flexible for this analysis. 
This is consistent with the best binding modes seen for 
the previous three ligands. The overlay of binding mode 3 
shows a clear shift in the ligand position, such that it binds deeper in the pocket – for an 
energetic demand. Though mode 1 is most likely to occur naturally, both are worth 
further analysis as no ligand so far as been able to produce this effect in silico.  
 
 
Figure 5.20 | Comparison of the four binding modes as determined by AutoDock Vina. 
 
Figure 5.19 | Overlay of the original 
ligand with binding modes 1 and 3. 
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Figure 5.21 | Key residue interactions of binding mode 1. 
As BDM41325 binding mode 1 holds a similar position in the ligand-binding channel as 
previous ligands (specifically BDM41907), similar residue interactions can be deduced 
(figure 5.21). The carboxyl group of the ligand appears likely to form the same 
hydrogen bond with Tyr140, and some stacking interaction is seen between Phe110 
and the benzyl-thiazole ring system of BDM41325. Though no interactions were 
suggested between Asn179, unlike in previous ligands, there is potential polar 
interaction between the carboxyl of the Asn176 side chain and N4 in the thiazole ring. 
When docked, this ligand adopts a conformation which prevents intramolecular 
interaction between S1 and N2 (section 5.4). 
 
Binding mode 3 results in some potential π-stacking between Phe110 and the piperidyl 
ring, and O3 may form a polar interaction with the sulphur atom of Met102. The 
inclusion of the original phenylalanine residues shows that this ligand orientation is 
impossible without the movement; the CF3 group on the carbon tail would not be able 
to take up that position. The movement of Phe 184 in particular opens out the channel 
and results in no discernable polar interactions for this CF3 group within 4 Å.  
Figure 5.22 | Key residue interactions of binding mode; original Phe orientations shown in pale blue. 
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CHAPTER 6 
CONCLUSIONS & MOVING FORWARD 
 
6.1 | Peptoid Precursors 
The three-dimensional structure given by crystallographic analysis of the precursor 
allows inference of the potential structure and intramolecular interactions of the 
resulting peptoid.  
 The anionic precursor form exemplifies alternate packing interactions to the 
protonated precursor form 82; each structure is distinct but the information taken 
together gives insight into what interactions the final peptoid could make. For example, 
the N1 and N2 atoms are available for ionic and hydrogen bond co-ordination. 
However, the NO2 group would not be present in the final peptoid, despite using 
localised charge to form ionic and hydrogen bonds in the anionic structure. Though 
there is no evidence of π-π stacking interactions within or between molecules, there is 
still the potential for stacking in a peptoid oligomer, depending upon the size and 
nature of the groups in the putative oligomer. 
 The crystallisation and structural characterization of these first two 
intermediates is a beginning towards creating a range of well-defined peptoids with 
designed, desired features for bonding and non-bonding interactions. This is a step 
forward in developing a toolbox of known peptoid conformations; a potential database 
of monomers which can be linked in silico to give theoretical ligands for virtual 
screening, which would be a powerful tool for future drug discovery. 
 
6.2 | EthR Inhibitors 
6.2.1 | Docking Results 
Based on the work done on EthR, the crystal packing structure of the inhibitor 
molecules allows inference of the potential interactions which could be made upon 
protein-ligand binding;7,9 therefore, the work detailed here would suggest that the 
protein-ligand binding is dominated by polar interactions and intermolecular hydrogen 
bonding. 
 The S1⋅⋅⋅N2 interaction seen in the single crystal structures of BDM31343 and 
BDM41325 were not upheld in the docking conformations derived from AutoDock 
Vina;10 this could suggest that while this is favourable in the packing structure, there 
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are overriding intermolecular interactions in the ligand-binding conformations which 
negate this specific bond. However, this cannot be deduced for certain because 
although empirical data is used to calculate the force fields, there is no term within Vina 
to define this kind of interaction. Therefore, this interaction being absent from the 
docking structures could be a result of a more favourable interaction between the 
ligand and protein, or simply a clear limitation of the docking algorithm. 
 Though the CF3 group has a demonstrated role in the packing structure of all 
three molecules which possess it, they play no role in the docking structures suggested 
– possibly because this group occupies the wider, open regions of the ligand-binding 
channel, either at the top or the aperture at the bottom, where no polar residues are 
within 4 Å. Therefore, while these groups do not show a role in ligand-binding, they 
could potentially contribute to penetrance into the mycobacterium, a proven role of 
fluorination.57 
 The only common source of intermolecular interaction displayed in the packing 
structures of all four structures is the formation of hydrogen bonds using the carboxyl 
atom O1. In the docking analysis, this atom forms interactions with Asn179 
(BDM41420) or Tyr148 (BDM41907 and BDM41325); BDM31343 shows this 
interaction in the packing, though not in the docking analysis, which suggests that while 
influential, this interaction is not solely responsible for protein-ligand binding. 
Alternatively, Asn176 plays an apparently critical role in all four docked structures, 
interacting with different parts of the molecule in each case. Similarly, in three out of 
the four structures, Phe110 shows potential non-polar interactions to contribute to the 
ligand binding. Overall, this indicates that no single interaction can be indicated as 
being responsible for inducing the inhibitory conformation of the protein; therefore, 
this is no potential gain in curtailing the ligand structure to specific atoms for 
interaction. 
 It is important to note that these residues are not conserved within the TetR-
like repressor family. There is a high sequence and three-dimensional structural 
similarity in the helix-turn-helix domain which binds DNA, which is not unexpected; 
however, there is no conservation of sequence in the non-DNA-binding domains.49 The 
range of functions covered by members of this repressor family require different 
control mechanisms, which accounts for this difference in ligand binding regions. 
 Though the opening of the auxiliary pocket (by the movement of Phe114 and 
Phe184) was demonstrated in the docking of BDM41325, there was a corresponding 
compromise in binding affinity. The inhibitor with the highest binding affinity                 
(-10 kcal mol-1) was BDM41907, neither the shortest nor the longest ligand of those 
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crystallised, suggesting that while the auxiliary pocket can be utilized, there is no 
benefit to a longer ligand with more atoms included for polar interactions. 
 
6.2.2 | Evaluation of Autodock Vina 
Each of the Vina runs is informative, even if only to give context to the highest ranked 
binding mode suggested; this is clearly demonstrated by the results for BDM41325, 
which showed there is an energetic compromise for the opening of the auxiliary 
binding pocket. For the other docking runs, where the differences were shown to be 
more subtle but no less significant, the results demonstrate that statistically minor 
changes in binding position can have a drastic effect on the binding affinity. Confidence 
in the highest ranked result can be drawn from the observation that the second-, third- 
and fourth-ranked results are feasible and still presented in the ligand-binding channel. 
 In my experience Vina is a powerful tool for molecular docking with a variety of 
user-definable parameters. The program can be adjusted to be comprehensive or fast 
depending upon the needs of the user, and repeated runs with the same data and 
parameters gives identical results; this allows the user to be confident in the derived 
values. 
 However, there are limitations to the program; the interface is not user-friendly 
and the preparation of the ligand and protein files is not trivial – tutorials are available 
but cover only the basic set-up and do not include instruction on creating a run with 
flexible side-chains. Also, it is insufficient to simply prepare the files, define a search 
grid and trust the data presented. The investigations into the program conducted in the 
course of this project indicated that the default exhaustiveness may be increased and 
give vastly different results; similarly the definition of the search grid was crucial. 
Though an increased exhaustiveness and a search grid encompassing the entire protein 
caused the run time to increase, the results were far more accurate and were 
reproducible. Iterative runs were required to find a compromise on how many flexible 
residues could be used in the docking in a reasonable length of time; a target of thirty 
minutes was used to ensure that the results could be achieved quickly, accurately and 
would be reproducible.  
 The most pressing limitation to Vina is that, although based upon empirical 
data, some parameters in the model do not have a corresponding term within the 
algorithm to include in the docking run. This was shown with the S1⋅⋅⋅N2 interaction in 
BDM31343 and BDM41325. This docking work bears repeating in a program with that 
additional coding to have absolute confidence in the results from Vina.  
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 In docking studies, small molecule crystal structures are essential. Three-
dimensional co-ordinates are an absolute requirement for the process, and while these 
can be achieved through ab initio computational approaches such as AMBER 89, a 
theoretical construct is no substitute from empirical data – particularly when the 
docking algorithm calculates force fields based upon empirical data. This approach is 
especially warranted when the target protein is difficult to crystallise or access to the 
protein is not possible; all that is needed is the PDB file and a small molecule structure 
for any scientist to evaluate the binding of a putative ligand. This has the added 
advantage of opening up research, particularly in the drug design field where one 
breakthrough can make a vast difference to the development process. 
 
6.2.3 | Moving Forward 
From here, the way forward is clear: biophysical characterization of the highest scoring 
inhibitors. This would require continued crystallisation of inhibitors in isolation, 
including those provided for this project, and the same analysis by docking; co-
crystallisation of these inhibitor-protein complexes would confirm the accuracy of the 
docking results to give proven confidence to the software-derived results. 
 This approach is not limited to EthR, or even the TetR family of repressors; 
steric hindrance as a mode of control can be adapted to a variety of regulatory proteins. 
Databases of small molecule structures such as the Cambridge Crystallographic 
Database, maintained by the CCDC (www.ccdc.cam.ac.uk), could be used to virtually 
screen ligands for target proteins, either as activators or inhibitors. DNA-binding 
proteins are a profound target for combating pathogens, as they have a direct effect on 
the life cycle or regulatory processes of the organism itself. A well-chosen and defined 
target would benefit from the approach detailed in this thesis. 
 Structure-based drug design, be it for a known target (EthR inhibitors) or for 
the purpose of creating lead fragments or adaptable monomers (the peptoid 
precursors) is a systematic and iterative method for the development of new drugs. X-
ray crystallography, while time and resource consuming, is a powerful method which 
feeds into this design process in ways no other structure-determination method is 
capable. Together, they allow us to find novel ways to combat long-standing known 
diseases, and can give us an arsenal against future and developing health crises. 
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APPENDIX 
A-I | Anionic Peptoid Precursor 
 
 Table A1 | Crystallographic Data for the Anionic Peptoid Precursor 
 
 Anionic Peptoid Precursor 
Empirical Formula C11H4N3O4F8Na 
Formula weight 382.14 
Temperature / K 99.69 
Crystal System monoclinic 
Space Group P21/n 
a / Å 5.635(2) 
b / Å 16.467(4) 
c / Å 16.432(4) 
α / ° 90.00 
β / ° 99.29(2) 
γ / ° 90.00 
Volume / Å3 1504.8(7) 
Z 4 
ρcalc / mg mm3 1.687 
µ /mm-1 1.925 
2  Range for Data Collection /° 7.66 – 132.86 
Index Ranges -6 ≤ h ≤ 5, -13 ≤ k ≤ 19, -19 ≤ l ≤ 14 
Reflections Collected 6216 
Independent Reflections 2304 [Rint = 0.0300] 
Data/Restraints/Parameters 2304/4/256 
Goodness-of-fit on F2 1.061 
Final R1 Index [I >2ς(I)  0.0366 
Final wR2 Index [I >2ς(I)  0.0974 
Final R1 Index [all data] 0.0445 
Final wR2 Index [all data] 0.1023 
Largest diff. peak/hole / e Å-3 0.250/-0.224 
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 Figure A1 | Labelled Anionic Peptoid Precursor 
 
  
 Table A2 | Bond lengths for the Anionic Peptoid Precursor 
 
Atom Atom Length / Å Atom Atom Length / Å 
O2 Na 2.356(8) C14 C15 1.373(16) 
Na O3 2.289(8) C15 F15 1.342(12) 
Na  O4 2.241(8) C15 C11 1.390(14) 
N3 O2 1.288(11) C1 C21 1.443(15) 
N3 O1 1.282(11) C21 C22 1.386(13) 
C1 N3 1.338(13) C22 F22 1.358(11) 
C1 C11 1.461(14) C22 C23 1.386(16) 
C11 C12 1.384(15) C23 F23 1.349(11) 
C12 C13 1.391(15) C23 N2 1.288(14) 
C12 F12 1.350(12) N2 C24 1.323(14) 
C13 F13 1.331(14) C24 F24 1.346(12) 
C13 N1 1.344(15) C24 C25 1.354(16) 
N1 C14 1.290(15) C25 F25 1.339(11) 
C14 F14 1.339(12) C25 C21 1.412(14) 
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 Table A3 | Selected bond angles for the Anionic Peptoid Precursor 
 
Atom Atom Atom Angle/ ° Atom  Atom Atom Angle /° 
O4 Na O3 118.9(9) F14 C14 C15 119.2(10) 
O4 Na O2 116.9(4) C14 C15 F15 119.5(9) 
O3 Na O2 122.4(3) C14 C15 C11 120.4(10) 
Na O2 N3 121.7(6) F15 C15 C11 120.1(10) 
O2 N3 O1 120.7(8) C15 C11 C12 114.9(10) 
O2 N3 C1 120.3(9) C1 C21 C22 122.0(9) 
O1 N3 C1 119.8(9) C21 C22 C23 120.9(9) 
N3 C1 C11 118.0(10) F22 C22 C23 119.8(9) 
N3 C1 C21 120.3(9) C22 C23 F23 117.6(9) 
C11 C1 C21 121.6(8) F23 C23 N2 118.1(9) 
C1 C11 C12 124.0(9) C23 N2 C24 115.9(9) 
C11 C12 F12 121.0(10) N2 C24 F24 115.0(9) 
C11 C12 C13 120.5(10) N2 C24 C25 125.5(10) 
F13 C13 N1 117.6(9) C24 C25 F25 120.2(9) 
C12 C13 N1 122.7(10) C24 C25 C21 119.6(9) 
C13 N1 C14 116.4(10) C25 C21 C1 124.0(9) 
N1 C14 F14 115.6(10) C25 C21 C22 113.9(9) 
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A-II | Protonated Peptoid Precursor 
 
 Table A4 | Crystallographic Data for the Protonated Peptoid Precursor 
 
 Protonated Peptoid Precursor 
Empirical Formula C11HN3O2F8 
Formula weight 359.15 
Temperature / K 99.81 
Crystal System monoclinic 
Space Group P21/n 
a / Å 8.552(2) 
b / Å 12.540(2) 
c / Å 11.831(2) 
α / ° 90.00 
β / ° 107.965(5) 
γ / ° 90.00 
Volume / Å3 1206.9(4) 
Z 4 
ρcalc / mg mm3 1.977 
µ /mm-1 2.022 
2  Range for Data Collection /° 10.56 – 133.28 
Index Ranges -10 ≤ h ≤ 10, -14 ≤ k ≤ 14, -14 ≤ l ≤ 13 
Reflections Collected 15399 
Independent Reflections 2068 [Rint = 0.0560] 
Data/Restraints/Parameters 2068/0/217 
Goodness-of-fit on F2 1.082 
Final R1 Index [I >2ς(I)  0.0532 
Final wR2 Index [I >2ς(I)  0.1540 
Final R1 Index [all data] 0.0561 
Final wR2 Index [all data] 0.1570 
Largest diff. peak/hole / e Å-3 0.531/-0.447 
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 Figure A2 | Labelled Protonated Peptoid Precursor 
 
 Table A5 | Bond lengths for the Protonated Peptoid Precursor 
 
Atom Atom Length / Å Atom Atom Length / Å 
O2 N3 1.246(4) C15 C11 1.389(4) 
O1 N3 1.200(4) C1 C21 1.514(4) 
N3 C1 1.487(4) C21 C22 1.379(4) 
C1 C11 1.503(4) C22 F22 1.336(3) 
C11 C12 1.372(4) C22 C23 1.380(4) 
C12 F12 1.331(3) C23 F23 1.325(3) 
C12 C13 1.377(5) C23 N2 1.307(4) 
C13 F13 1.330(4) N2 C24 1.311(4) 
C13 N1 1.297(4) C24 F24 1.334(4) 
N1 C14 1.295(4) C24 C25 1.376(4) 
C14 F14 1.333(3) C25 F25 1.332(3) 
C14 C15 1.371(4) C25 C21 1.380(4) 
C15 F15 1.337(3)    
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Table A6 | Bond angles for the Protonated Peptoid Precursor 
 
Atom Atom Atom Angle /° Atom Atom Atom Angle /° 
O1 N3 O2 123.9(3) F15 C15 C11 120.5(3) 
O1 N3 C1 120.4(3) C15 C11 C12 115.7(3) 
O2 N3 C1 115.6(3) C15 C11 C1 123.8(2) 
N3 C1 C11 111.4(2) C1 C21 C22 125.3(3) 
N3 C1 C21 111.9(2) C21 C22 F22 121.0(2) 
C11 C1 C21 113.3(2) F22 C22 C23 119.3(2) 
C1 C11 C12 120.5(3) C21 C22 C23 119.7(3) 
C11 C12 F12 120.8(3) C22 C23 F23 118.9(3) 
C11 C12 C13 119.2(3) C22 C23 N2 123.8(3) 
F12 C12 C13 119.9(3) F23 C23 N2 117.3(3) 
C12 C13 F13 118.2(3) C23 N2 C24 116.8(3) 
F13 C13 N1 117.4(3) N2 C24 F24 116.4(3) 
C12 C13 N1 124.5(3) N2 C24 C25 124.0(3) 
C13 N1 C14 117.1(3) F24 C24 C25 119.6(3) 
N1 C14 F14 117.2(3) C24 C25 F25 120.5(3) 
N1 C14 C15 123.7(3) C24 C25 C21 119.6(3) 
F14 C14 C15 119.1(3) F25 C25 C21 119.9(3) 
C14 C15 F15 119.7(3) C25 C21 C1 118.6(2) 
C14 C15 C11 119.8(3) C25 C21 C22 116.1(3) 
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A-III | BDM31343 
 
 Table A7 | Crystallographic Data for BDM31343 
 
 BDM31343 
Empirical Formula C14H14N4O2S 
Formula weight 302.35 
Temperature / K 99.80 
Crystal System monoclinic 
Space Group P21/c 
a / Å 6.834(2) 
b / Å 16.923(3) 
c / Å 12.531(2) 
α / ° 90.00 
β / ° 104.882(5) 
γ / ° 90.00 
Volume / Å3 1400.6(5) 
Z 4 
ρcalc / mg mm3 1.434 
µ /mm-1 2.153 
2  Range for Data Collection /° 8.98 – 133.28 
Index Ranges -8 ≤ h ≤ 8, -19 ≤ k 20, -14 ≤ l ≤ 14  
Reflections Collected 23371 
Independent Reflections 2429 [Rint = 0.0320] 
Data/Restraints/Parameters 2429/0/190 
Goodness-of-fit on F2 1.175 
Final R1 Index [I >2ς(I)  0.0316 
Final wR2 Index [I >2ς(I)  0.0916 
Final R1 Index [all data] 0.0326 
Final wR2 Index [all data] 0.1003 
Largest diff. peak/hole / e Å-3 0.286/-0.393 
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 Figure A3 | Labelled BDM31343 
 
 Table A8 | Bond lengths for BDM31343 
 
Atom Atom Length /Å Atom Atom Length /Å 
S1 C8 1.727(3) C3 C2 1.532(2) 
C8 C9 1.379(2) C2 C1 1.525(2) 
C9 C10 1.425(2) C1 N1 1.472(3) 
C10 C11 1.353(3) N1 C5 1.465(2) 
C11 S1 1.714(9) C5 C4 1.517(2) 
C8 C7 1.450(2) C4 C3 1.537(2) 
C7 N2 1.310(2) N1 C12 1.343(2) 
N2 O2 1.417(4) C12 O1 1.229(2) 
O2 C6 1.351(2) C12 C13 1.532(2) 
C6 N3 1.299(2) C13 C14 1.463(2) 
N3 C7 1.383(2) C14 N4 1.145(2) 
C6 C3 1.485(2)    
 
 
 Table A9 | Bond angles for BDM31343 
 
Atom Atom Atom Angle /° Atom Atom Atom Angle /° 
S1 C8 C9 111.7(13) C6 C3 C2 112.5(13) 
C8 C9 C10 111.4(16) C6 C3 C4 109.5(13) 
C9 C10 C11 113.3(16) C4 C3 C2 109.6(13) 
C10 C11 S1 112.1(14) C3 C4 C5 109.6(14) 
C11 S1 C8 91.39(9) C4 C5 N1 110.6(13) 
S1 C8 C7 121.7(13) C5 N1 C1 114.0(13) 
C9 C8 C7 126.5(16) N1 C1 C2 110.9(13) 
C8 C7 N2 155.5(16) C1 C2 C3 110.6(13) 
C8 C7 N3 122.5(15) C5 N1 C12 125.2(14) 
N2 C7 N3 114.9(15) C1 N1 C12 120.2(14) 
C7 N3 C6 102.5(14) N1 C12 C13 120.2(15) 
N3 C6 O2 113.3(14) N1 C12 O1 123.9(16) 
C6 O2 N2 106.4(12) O1 C12 C13 120.2(15) 
C7 N2 O2 102.9(13) C12 C13 C14 111.3(14) 
O2 C6 C3 117.2(14) C13 C14 N4 177.1(19) 
N3 C6 C3 129.5(15)     
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A-IV | BDM41420 
 
 Table A11 | Crystallographic Data for BDM41420 
 
 BDM41420 
Empirical Formula C17H19N2O2F3 
Formula weight 300.35 
Temperature / K 100.0 
Crystal System monoclinic 
Space Group P21/c 
a / Å 10.599(3) 
b / Å 29.145(2) 
c / Å 10.661(2) 
α / ° 90.00 
β / ° 102.669(2) 
γ / ° 90.00 
Volume / Å3 3213.3(8) 
Z 8 
ρcalc / mg mm3 1.242 
µ /mm-1 0.621 
2  Range for Data Collection /° 6.06 – 136.96 
Index Ranges -12 ≤ h 12, -34 ≤ k ≤ 33, -12 ≤ l ≤ 12 
Reflections Collected 20222 
Independent Reflections 5615 [Rint = 0.0213] 
Data/Restraints/Parameters 5615/0/449 
Goodness-of-fit on F2 1.294 
Final R1 Index [I >2ς(I)  0.0351 
Final wR2 Index [I >2ς(I)  0.1366 
Final R1 Index [all data] 0.0395 
Final wR2 Index [all data] 0.1533 
Largest diff. peak/hole / e Å-3 0.263/-0.229 
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 Figure A4 | Labelled BDM41420 (1) 
 
 Table A12 | Bond lengths for BDM41420 (1) 
 
Atom Atom Length /Å Atom Atom Length /Å 
C8 C9 1.385(17) C2 C1 1.526(17) 
C9 C10 1.391(17) C1 N1 1.464(14) 
C10 C11 1.374(18) N1 C5 1.465(14) 
C11 C12 1.383(18) C5 C4 1.527(15) 
C12 C13 1.389(17) C4 C3 1.526(15) 
C13 C8 1.389(17) N1 C14 1.354(15) 
C8 C7 1.472(15) C14 O1 1.232(14) 
C7 N2 1.283(15) C14 C15 1.522(16) 
N2 O2 1.424(12) C15 C16 1.523(16) 
O2 C3 1.475(14) C16 C17 1.493(16) 
C3 C6 1.521(16) C17 F1 1.345(14) 
C6 C7 1.505(16) C17 F2 1.345(14) 
C3 C2 1.521(16) C17 F3 1.340(15) 
 
  
 Table A13 | Bond angles for BDM41420 (1) 
 
Atom Atom Atom Angle /° Atom Atom Atom Angle /° 
C8 C9 C10 120.6(12) C2 C3 C4 110.8(9) 
C9 C10 C11 120.3(12) C3 C4 C5 111.2(9) 
C10 C11 C12 119.5(12) N1 C5 C4 109.5(9) 
C11 C12 C13 120.4(12) C1 N1 C5 112.9(9) 
C8 C13 C12 120.4(12) N1 C1 C2 110.4(9) 
C9 C8 C13 118.8(11) C1 C2 C3 112.3(10) 
C7 C8 C9 120.1(11) C14 N1 C5 124.5(9) 
C7 C8 C13 121.2(11) C14 C15 C1 120.0(10) 
N2 C7 C6 121.3(10) O1 C14 N1 122.5(11) 
C6 C7 C8 125.3(10) O1 C14 C15 120.5(10) 
N2 C7 C6 113.5(10) N1 C14 C15 116.9(10) 
C7 N2 O2 108.6(9) C14 C15 C16 110.8(9) 
N2 O2 C3 107.9(8) C15 C16  C17  111.5(9) 
O2 C3 C6 102.5(8) C16 C17 F1 112.1(10) 
C3 C6 C7 100.4(9) C16 C17 F2 113.0(10) 
O2 C3 C2 107.7(9) C16 C17 F3 112.9(10) 
O2 C3 C4 107.2(9) F1 C17 F2 106.5(10) 
C6 C3 C2 115.2(10) F2 C17 F3 105.8(10) 
C4 C3 C6 112.8(10) F1 C17 F3 105.9(10) 
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 Figure A5 | Labelled BDM41420 (2) 
 
 Table A14 | Bond lengths for BDM41420 (2) 
 
Atom Atom Length /Å Atom Atom Length /Å 
C25 C26 1.395(17) C19 C18 1.526(16) 
C26 C27 1.390(17) C18 N3 1.471(14) 
C27 C28 1.387(2) N3 C22 1.463(15) 
C28 C29 1.379(2) C22 C21 1.530(18) 
C29 C30 1.391(18) C21 C20 1.523(16) 
C30 C25 1.389(18) N3 C31 1.353(15) 
C25 C24 1.471(16) C31 O3 1.230(14) 
C24 N4 1.285(15) C31 C32 1.522(16) 
N4 O4 1.421(12) C32 C33 1.527(16) 
O4 C20 1.475(14) C33 C34 1.492(16) 
C20 C23 1.521(16) C34 F4 1.347(14) 
C23 C24 1.503(16) C34 F5 1.346(15) 
C20 C19 1.528(15) C34 F6 1.347(14) 
 
 Table A15 | Bond angles for BDM41420 (2) 
 
Atom Atom Atom Angle /° Atom Atom Atom Angle /° 
C27 C26 C25 120.3(12) C21 C20 C19 110.6(9) 
C28 C27 C26 120.2(12) C18 C19 C20 111.3(9) 
C29 C28 C27 119.8(12) C20 C21 C22 111.6(10) 
C28 C29 C30 120.3(13) N3 C22 C21 110.1(9) 
C25 C30 C29 120.4(12) N3 C18 C19 109.7(9) 
C30 C25 C26 119.1(11) C31 N3 C18 124.9(10) 
C30 C25 C24 120.2(11) C22 N3 C18 113.0(9) 
C26 C25 C24 120.7(11) C31 N3 C22 119.6(10) 
C25 C24 C23 125.2(10) O3 C31 N3 122.3(11) 
N4 C24 C25 121.3(10) N3 C31 C32 116.9(10) 
N4 C24 C23 113.4(10) O3 C31 C32 120.8(10) 
C24 C23 C20 108.8(9) C31 C32 C33 110.6(9) 
N4 O4 C20 108.0(13) C34 C33 C32 111.6(9) 
C24 C23 C20 100.5(9) C33 C34 F4 113.1(10) 
O4 C20 C23 102.8(8) C33 C34 F5 112.0(10) 
C23 C20 C19 112.2(10) C33 C34 F6 113.0(10) 
O4 C20 C21 107.7(9) F4 C34 F5 105.8(10) 
O4 C20 C19 107.3(9) F4 C34 F6 106.0(10) 
C23 C20 C21 115.5(10) F5 C34 F6 106.5(10) 
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A-V | BDM41907 
 
 Table A17 | Crystallographic Data for BDM41907 
 
 BDM41907 
Empirical Formula C19H22N3O4SF3 
Formula weight 371.44 
Temperature / K 99.85 
Crystal System monoclinic 
Space Group P21/c 
a / Å 10.702(6) 
b / Å 19.853(2) 
c / Å 9.873(2) 
α / ° 90.00 
β / ° 104.568(2) 
γ / ° 90.00 
Volume / Å3 2030.4(5) 
Z 4 
ρcalc / mg mm3 1.215 
µ /mm-1 1.622 
2  Range for Data Collection /° 8.54 – 132.38 
Index Ranges -12 ≤ h ≤ 11, -23 ≤ k ≤ 23, -10 ≤ l ≤ 11 
Reflections Collected 14675 
Independent Reflections 3493 [Rint = 0.0408] 
Data/Restraints/Parameters 3493/0/272 
Goodness-of-fit on F2 0.992 
Final R1 Index [I >2ς(I)  0.0386 
Final wR2 Index [I >2ς(I)  0.1163 
Final R1 Index [all data] 0.0498 
Final wR2 Index [all data] 0.1271 
Largest diff. peak/hole / e Å-3 0.395/-0.332 
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 Figure A6 | Labelled BDM41907 
 
 Table A18 | Bond lengths for BDM41907 
 
Atom Atom Length /Å Atom Atom Length /Å 
C19 S1 1.761(2) C6 C3 1.492(3) 
S1 O3 1.442(15) C3 C2 1.534(2) 
S1 O4 1.432(15) C2 C1 1.525(3) 
S1 C11 1.771(2) C1 N1 1.462(2) 
C11 C10 1.389(3) N1 C5 1.468(2) 
C10 C9 1.381(3) C5 C4 1.524(3) 
C9 C8 1.393(3) C4 C3 1.536(2) 
C8 C13 1.389(3) N1 C14 1.353(2) 
C13 C12 1.387(3) C14 O1 1.239(2) 
C12 C11 1.386(3) C14 C15 1.525(3) 
C8 C7 1.474(3) C15 C16 1.525(3) 
C7 N3 1.381(2) C16 C17 1.524(3) 
N3 C6 1.298(2) C17 C18 1.492(3) 
C6 O2 1.346(2) C18 F1 1.340(3) 
O2 N2 1.409(2) C18 F2 1.342(2) 
N2 C7 1.307(2) C18 F3 1.351(2) 
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Table A19 | Bond angles for BDM41907 
 
Atom Atom Atom Angle /° Atom Atom Atom Angle /° 
O4 S1 O3 119.0(9) C7 N2 O2 103.1(15) 
O4 S1 C11 108.1(9) C2 C3 C4 110.5(15) 
O4 S1 C19 108.6(10) C6 C3 C2 111.0(15) 
O3 S1 C11 108.1(9) C6 C3 C4 111.2(15) 
O3 S1 C19 108.0(10) C1 C2 C3 110.5(15) 
C19 S1 C11 104.1(10) N1 C1 C2 110.0(15) 
C12 C11 S1 120.0(14) C14 N1 C5 125.9(16) 
C12 C11 C10 121.0(18) C14 N1 C1 120.8(15) 
C10 C11 S1 119.0(15) C1 N1 C5 113.2(15) 
C9 C10 C11 119.7(18) N1 C5 C4 110.8(15) 
C10 C9 C8 119.8(18) C5 C4 C3 111.6(15) 
C9 C8 C7 119.2(17) O1 C14 N1 121.3(17) 
C13 C8 C9 120.3(18) O1 C14 C15 120.3(17) 
C13 C8 C7 120.4(17) N1 C14 C15 118.4(16) 
C12 C13 C8 120.0(18) C16 C15 C14 111.5(16) 
N2 C7 C8 123.5(16) C17 C16 C15 111.5(16) 
N3 C7 C8 114.7(17) C18 C17 C16 111.7(18) 
N2 C7 N3 121.7(17) F3 C18 C17 113.2(17) 
C6 N3 C7 102.5(15) F2 C18 F3 105.5(17) 
O2 C6 C3 117.8(16) F2 C18 C17 113.4(17) 
N3 C6 O2 113.1(16) F1 C18 F3 105.7(18) 
N3 C6 C3 129.1(16) F1 C18 F2 105.8(17) 
C6 O2 N2 106.6(14) F1 C18 C17 112.6(18) 
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A-VI | BDM41325 
 
 Table A21 | Crystallographic Data for BDM41325 
 
 BDM41325 
Empirical Formula C19H19N4O3F3S 
Formula weight 440.44 
Temperature / K 99.93 
Crystal System orthorhombic 
Space Group P212121 
a / Å 4.828(1) 
b / Å 16.186(5) 
c / Å 24.332(7) 
α / ° 90.00 
β / ° 90.00 
γ / ° 90.00 
Volume / Å3 1901.56(9) 
Z 4 
ρcalc / mg mm3 1.538 
µ /mm-1 2.059 
2  Range for Data Collection /° 6.56 – 132.92 
Index Ranges -5 ≤ h ≤ 5, -19 ≤ k ≤ 19, -28 ≤ l ≤ 28 
Reflections Collected 19327 
Independent Reflections 3233 [Rint = 0.0436] 
Data/Restraints/Parameters 3233/0/272 
Goodness-of-fit on F2 0.979 
Final R1 Index [I >2ς(I)  0.0298 
Final wR2 Index [I >2ς(I)  0.0761 
Final R1 Index [all data] 0.0333 
Final wR2 Index [all data] 0.0788 
Largest diff. peak/hole / e Å-3 0.256/-0.165 
 
 
 
 
 
 
 
 
 
 
 
 
105 
 Figure A7 | Labelled BDM41325 
 
 Table A22 | Bond lengths for BDM41325 
 
Atom Atom Length /Å Atom Atom Length /Å 
C19 O3 1.443(3) N3 C7 1.376(3) 
O3 C12 1.368(3) C6 C3 1.487(3) 
C12 C13 1.368(3) C3 C2 1.539(3) 
C13 C14 1.391(3) C2 C1 1.522(3) 
C14 C9 1.402(3) C1 N1 1.456(3) 
C9 C10 1.406(3) N1 C5 1.466(3) 
C10 C11 1.364(3) C5 C4 1.522(3) 
C11 C12 1.412(3) C4 C3 1.535(3) 
C14 S1 1.735(2) N1 C15 1.350(3) 
S1 C8 1.754(2) C15 O1 1.224(3) 
C8 N4 1.303(3) C15 C16 1.525(3) 
N4 C9 1.389(3) C16 C17 1.525(3) 
C8 C7 1.455(3) C17 C18 1.488(3) 
C7 N2 1.313(3) C18 F1 1.351(3) 
N2 O2 1.417(2) C18 F2 1.339(2) 
O2 C6 1.349(2) C18 F3 1.348(2) 
C6 N3 1.298(3)    
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Table A23 | Bond angles for BDM41325 
 
Atom Atom Atom Angle /° Atom Atom Atom Angle /° 
C12 O3  C19 117.0(17) N3 C6 O2 113.6(19) 
O3 C12 C13 124.2(18) N3 C6 C3 128.1(19) 
O3 C12 C11 115.0(19) C6 N3 C7 102.5(17) 
C13 C12 C11 120.8(2) C6 C3 C4 109.9(18) 
C12 C13 C14 117.3(18) C6 C3 C2 110.3(17) 
C9 C14 S1 109.2(16) C2 C3 C4 110.3(16) 
C13 C14 S1 128.1(16) C1 C2 C3 111.9(17) 
C13 C14 C9 122.7(19) N1 C1 C2 110.4(18) 
N4 C9 C14 115.8(18) C15 N1 C5 119.9(19) 
N4 C9 C10 125.4(18) C15 N1 C1 126.0(17) 
C14 C9 C10 118.8(19) C1 N1 C5 114.1(17) 
C11 C10 C9 119.1(19) N1 C5 C4 110.7(17) 
C10 C11 C12 121.3(2) C5 C4 C3 110.9(19) 
C14 S1 C8 88.8(10) O1 C15 N1 122.1(19) 
C7 C8 S1 120.4(15) O1 C15 C16 120.7(19) 
N4 C8 S1 116.1(16) N1 C15 C16 117.2(19) 
N4 C8 C7 123.5(18) C17 C16 C15 110.7(18) 
C8 N4 C9 110.0(17) C18 C17 C16 111.8(18) 
N2 C7 N3 114.9(2) F3 C18 F1 105.3(18) 
N2 C7 C8 122.0(18) F3 C18 C17 112.6(18) 
N3 C7 C8 123.1(18) F2 C18 F3 106.2(18) 
C7 N2 O2 103.0(15) F2 C18 F1 106.2(18) 
C6 O2 N2 106.0(15) F2 C18 C17 112.7(18) 
O2 C6 C3 118.3(18) F1 C18 C17 113.3(19) 
 
 
 
